Origin Materials (ORGN) 10-K23 Feb 232022 FY Annual reportFinancial data

Company Profile

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
Cover Page - USD ($) $ in Millions	Dec. 31, 2022	Feb. 16, 2023	Jun. 30, 2022
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-39378
Entity Registrant Name	ORIGIN MATERIALS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-1388928
Entity Address, Address Line One	930 Riverside Parkway
Entity Address, Address Line Two	Suite 10
Entity Address, City or Town	West Sacramento,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95605
City Area Code	916
Local Phone Number	231-9329
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 630.1
Entity Common Stock, Shares Outstanding		143,099,850
Documents Incorporated by Reference	Specified portions of the registrant’s definitive proxy statement to be issued in conjunction with the registrant’s 2023 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant’s fiscal year ended December 31, 2022 ("Proxy Statement"), are incorporated by reference into Part III of this Annual Report on Form 10-K (this "Annual Report"). Except as expressly incorporated by reference, the registrant’s Proxy Statement shall not be deemed to be a part of this Annual Report.
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0001802457
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ORGN
Security Exchange Name	NASDAQ
Warrant
Document Information [Line Items]
Title of 12(b) Security	Warrants
Trading Symbol	ORGNW
Security Exchange Name	NASDAQ

Audit Information

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2022
Audit Information [Abstract]
Auditor Firm ID	248
Auditor Name	GRANT THORNTON LLP
Auditor Location	San Jose, California

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 107,858	$ 46,637
Restricted cash	490	490
Marketable securities	215,464	397,458
Other receivables	4,346	2,612
Derivative asset	0	202
Prepaid expenses and other current assets	3,341	3,774
Total current assets	331,499	451,173
Property, plant, and equipment, net	154,183	57,185
Operating lease right-of-use asset	2,779	1,782
Intangible assets, net	160	215
Other long-term assets	5,079	62
Total assets	493,700	510,417
Current liabilities
Accounts payable	10,384	2,451
Accrued expenses	8,414	973
Operating lease liability, current	619	280
Other liabilities, current	51	380
Derivative liability	344	103
Total current liabilities	19,812	4,187
Earnout liability	42,533	127,757
Canadian government research and development program liability	7,185	6,762
Assumed common stock warrants liability	30,872	52,860
Stockholder note	5,847	5,189
Related party other liabilities, long-term	5,395	5,720
Operating lease liability	2,249	1,486
Other liabilities, long-term	2,902	2,946
Total liabilities	116,795	206,907
Commitments and contingencies (See Note 19)
STOCKHOLDERS’ EQUITY
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2022 and 2021	0	0
Common stock, $0.0001 par value, 1,000,000,000 shares authorized; 143,034,225 and 141,301,569, issued and outstanding as of December 31, 2022 and 2021, respectively (including 4,500,000 Sponsor Vesting Shares)	14	16
Additional paid-in capital	371,072	361,542
Retained earnings (Accumulated deficit)	21,772	(56,797)
Accumulated other comprehensive loss	(15,953)	(1,251)
Total stockholders’ equity	376,905	303,510
Total liabilities and stockholders’ equity	$ 493,700	$ 510,417

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	143,034,225	141,301,569
Common stock, shares outstanding (in shares)	143,034,225	141,301,569
Sponsor vesting shares issued (in shares)	4,500,000	4,500,000
Sponsor vesting shares outstanding (in shares)	4,500,000	4,500,000

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Operating expenses
Research and development	$ 14,141	$ 9,124	$ 4,138
General and administrative	24,095	17,265	6,563
Depreciation and amortization	711	544	479
Total operating expenses and loss from operations	38,947	26,933	11,180
Other (income) expenses
Interest income	(8,825)	(1,413)	0
Interest expense, net of capitalized interest	0	2,838	341
Change in fair value of derivatives	443	1,326	1,088
Change in fair value of warrants liability	(21,988)	4,525	18,498
Change in fair value of earnout liability	(85,437)	(75,488)	0
Other income, net	(1,709)	(811)	(805)
Total other (income) expenses, net	(117,516)	(69,023)	19,122
Net income (loss)	78,569	42,090	(30,302)
Other comprehensive income (loss)
Unrealized loss on marketable securities	(8,014)	(1,712)	0
Foreign currency translation adjustment, net of tax	(6,688)	77	794
Total comprehensive income (loss)	$ 63,867	$ 40,455	$ (29,508)
Net income (loss) per share, basic (in dollars per share)	$ 0.57	$ 0.42	$ (0.48)
Net income (loss) per share, diluted (in dollars per share)	$ 0.55	$ 0.40	$ (0.48)
Weighted-average common shares outstanding, basic (in shares)	137,563,877	101,221,781	62,544,933
Weighted-average common shares outstanding, diluted (in shares)	142,146,767	106,237,754	62,544,933

Consolidated Statements of Rede

Consolidated Statements of Redeemable Convertible Preferred Stock, Stockholders' Equity and Accumulated Other Comprehensive Income (Loss) - USD ($) $ in Thousands	Total	Series A	Series B	Series C	Previously Reported	Previously Reported Series A	Previously Reported Series B	Previously Reported Series C	Revision of Prior Period, Adjustment	Revision of Prior Period, Adjustment Series A	Revision of Prior Period, Adjustment Series B	Revision of Prior Period, Adjustment Series C	Legacy Origin Common Stock	Legacy Origin Common Stock Previously Reported	Legacy Origin Common Stock Revision of Prior Period, Adjustment	Common Stock	Common Stock Previously Reported	Common Stock Revision of Prior Period, Adjustment	Additional Paid-in Capital	Additional Paid-in Capital Previously Reported	Additional Paid-in Capital Revision of Prior Period, Adjustment	(Accumulated Deficit) Retained Earnings	(Accumulated Deficit) Retained Earnings Previously Reported	Accumulated Other Comprehensive Income (loss)	Accumulated Other Comprehensive Income (loss) Previously Reported
Balance beginning (in shares) at Dec. 31, 2019													0	1,283,788	(1,283,788)	62,542,363	0	62,542,363
Balance beginning at Dec. 31, 2019	$ 27,999				$ (67,984)				$ 95,983				$ 0	$ 0		$ 6	$ 0	$ 6	$ 96,988	$ 1,011	$ 95,977	$ (68,585)	$ (68,585)	$ (410)	$ (410)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of stock options	2																		2
Common stock issued upon exercise of stock options (in shares)																2,912
Stock-based compensation	1,630																		1,630
Net (loss) income	(30,302)																					(30,302)
Other comprehensive loss	794																							794
Ending balance at Dec. 31, 2020	123															$ 6			98,620			(98,887)		384
Ending balance (in shares) at Dec. 31, 2020																62,545,275
Beginning balance (in shares) at Dec. 31, 2019		0	0	0		13,204,284	6,275,704	1,590,675		(13,204,284)	(6,275,704)	(1,590,675)
Beginning balance at Dec. 31, 2019		$ 0	$ 0	$ 0		$ 31,478	$ 41,125	$ 23,380		$ (31,478)	$ (41,125)	$ (23,380)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of stock options	77															$ 3			74
Common stock issued upon exercise of stock options (in shares)																171,118
Stock-based compensation	5,767																		5,767
Reclassification of stockholders' convertible notes payable (in shares)																2,049,191
Reclassification of stockholders’ convertible notes payable	20,491																		20,491
Reclassification of redeemable convertible preferred stock warrant liability (in shares)																5,554,440
Reclassification of redeemable convertible preferred stock warrant liability	54,274															$ 7			54,267
Business Combination, net of redemptions and equity issuance costs of $37 million (in shares)																70,981,545
Business Combination, net of redemptions and equity issuance costs of $37 million	385,405																		385,405
Reclassification of equity to liability related to earn out provisions of Business Combination (see note 13)	(203,082)																		(203,082)
Net (loss) income	42,090																					42,090
Other comprehensive loss	(1,635)																							(1,635)
Ending balance at Dec. 31, 2021	303,510															$ 16			361,542			(56,797)		(1,251)
Ending balance (in shares) at Dec. 31, 2021																141,301,569
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued upon exercise of stock options	401																		401
Common stock issued upon exercise of stock options (in shares)																1,412,226
Stock-based compensation	9,129																		9,129
Immediately vested common stock awards	(2)															$ (2)
Immediately vested common stock awards (in shares)																320,430
Net (loss) income	78,569																					78,569
Other comprehensive loss	(14,702)																							(14,702)
Ending balance at Dec. 31, 2022	$ 376,905															$ 14			$ 371,072			$ 21,772		$ (15,953)
Ending balance (in shares) at Dec. 31, 2022																143,034,225

Consolidated Statements of Re_2

Consolidated Statements of Redeemable Convertible Preferred Stock, Stockholders' Equity and Accumulated Other Comprehensive Income (Loss) (Parenthetical) $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)
Statement of Stockholders' Equity [Abstract]
Equity issuance costs	$ 37

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net income (loss)	$ 78,569,000	$ 42,090,000	$ (30,302,000)
Adjustments to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization	711,000	544,000	479,000
Amortization on right-of-use asset	582,000	280,000	0
Stock-based compensation	7,235,000	5,767,000	1,630,000
Amortization of debt issuance costs	0	14,000	90,000
Accretion of debt discount	0	2,211,000	101,000
Change in fair value of derivatives	443,000	1,326,000	1,088,000
Change in fair value of common stock warrants liability	(21,988,000)	(30,510,000)	0
Change in fair value of preferred stock warrants liability	0	35,035,000	18,498,000
Change in fair value of earnout liability	(85,437,000)	(75,488,000)	0
Changes in operating assets and liabilities:
Other receivables	(1,734,000)	(2,563,000)	1,007,000
Grants receivable	0	0	87,000
Prepaid expenses and other current assets	432,000	(3,652,000)	53,000
Other long-term assets	(5,017,000)	0	0
Accounts payable	26,000	(395,000)	1,203,000
Accrued expenses	485,000	3,010,000	349,000
Payment on operating lease liabilities	(572,000)	(295,000)	0
Other liabilities, current	(329,000)	380,000	0
Other liabilities, long-term	502,000	203,000	256,000
Net cash used in operating activities	(26,092,000)	(22,043,000)	(5,461,000)
Cash flows from investing activities
Purchases of property, plant, and equipment, net of grants	(83,691,000)	(12,268,000)	(1,786,000)
Purchases of marketable securities	(3,823,407,000)	(2,448,316,000)	0
Sales of marketable securities	3,815,859,000	2,024,089,000	0
Maturities of marketable securities	180,331,000	25,058,000	0
Capitalized interest on plant construction	(245,000)	(201,000)	(268,000)
Net cash provided by (used in) investing activities	88,847,000	(411,638,000)	(2,054,000)
Cash flows from financing activities
Proceeds from stockholders' notes payable, net of debt issuance costs	0	11,707,000	3,166,000
Payment of short-term debt	0	(906,000)	0
Proceeds from Canadian Government Research and Development Program	849,000	543,000	2,662,000
Proceeds from exercise of stock options	399,000	74,000	1,000
Business combination, net of issuance costs paid	0	467,530,000	0
Net cash provided by financing activities	1,248,000	478,948,000	5,829,000
Effects of foreign exchange rate changes on the balance of cash and cash equivalents, and restricted cash held in foreign currencies	(2,782,000)	(14,000)	(52,000)
Net increase (decrease) in cash and cash equivalents, and restricted cash	61,221,000	45,253,000	(1,738,000)
Cash and cash equivalents, and restricted cash, beginning of the period	47,127,000	1,874,000	3,612,000
Cash and cash equivalents, and restricted cash, end of the period	108,348,000	47,127,000	1,874,000
Supplemental disclosure of cash flow information
Conversion of stockholder convertible notes payable to common stock	0	20,493,000	0
Reclassification of redeemable convertible preferred stock warrants to common stock	0	54,267,000	0
Reclassification of contingently issued equity to liability	0	203,082,000	0
Net assets assumed from business combination	0	81,364,000	0
Debt discount related to derivative liability	0	2,196,000	0
Business combination transaction costs, accrued but not paid	0	609,000	0
Operating lease right-of-use assets obtained in exchange for lease obligations	1,687,000	2,062,000	0
Stock-based compensation capitalized into property, plant, and equipment	1,894,000	0	0
Purchases of fixed assets included in accounts payable and accrued expenses	$ 17,085,000	$ 0	$ 0

Organization and Business

Organization and Business	12 Months Ended
Organization and Business	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	Organization and Business Unless the context otherwise requires, references in these notes to “Origin”, “the Company”, “we”, “us” and “our” and any related terms are intended to mean the post-Business Combination Origin Materials, Inc. and its consolidated subsidiaries. The Company’s mission is to help enable the world’s transition to sustainable materials by replacing petroleum-based materials with decarbonized materials in a wide range of end products, such as food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments and more. The Company’s technology can convert sustainable feedstocks, such as sustainably harvested wood, agricultural waste, wood waste and corrugated cardboard, into materials and products that are currently made from fossil feedstocks, such as petroleum and natural gas. The Company’s products are intended to compete directly with petroleum-derived products on both performance and price, as well as provide a significant unit cost advantage over products made from other low-carbon feedstocks. The Company achieved the mechanical completion of its first manufacturing plan in Ontario, Canada ("Origin 1") and is currently in the process of commissioning the plant. The Company is also currently in the planning phase for the construction of a significantly larger manufacturing plant ("Origin 2"). On June 25, 2021 (the “Closing Date”), Artius Acquisition Inc. (“Artius”), a special purpose acquisition company, consummated the Merger Agreement and other Related Agreements (the “Merger Agreement”) dated February 16, 2021, by and among Artius, Zero Carbon Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Artius (“Merger Sub”), and Micromidas, Inc. a Delaware corporation (now known as Origin Materials Operating Inc., (“Legacy Origin”)). Pursuant to the terms of the Merger Agreement, a business combination between Artius and Legacy Origin was effected through the merger of Merger Sub with and into Legacy Origin, with Legacy Origin surviving as the surviving company and as a wholly-owned subsidiary of Artius (the “Merger” and, collectively with the other transactions described in the Merger Agreement, the “Business Combination”). On the Closing Date, Artius changed its name to Origin Materials, Inc. (collectively with its subsidiaries, the “Company”). For additional information on the Business Combination, please refer to Note 4, Business Combination , to these consolidated financial statements.

Risks and Liquidity

Risks and Liquidity	12 Months Ended
Risks and Liquidity	Dec. 31, 2022
Risks And Liquidity [Abstract]
Risks and Liquidity	Risks and Liquidity The Company believes that the Business Combination has provided substantial liquidity and that its $323.8 million of cash and cash equivalents, restricted cash, and marketable securities will enable it to fund its planned operations for at least twelve months from the issuance date of these consolidated financial statements. Beginning in March 2020, the COVID-19 pandemic and the measures imposed to contain this pandemic have disrupted and are expected to continue to impact the Company’s business. The magnitude of the impact of the COVID-19 pandemic on the Company’s productivity, results of operations and financial position, and its disruption to the Company’s business and timeline, will depend in part, on the length and severity of these restrictions and on the Company’s ability to conduct business in the ordinary course. We continue to monitor the rapidly evolving conditions and circumstances, as well as guidance from international and domestic authorities, including public health authorities, and we may need to take additional actions based on their recommendations. While the level of disruption caused by, and the economic impact of, COVID-19 has lessened in 2022, there is no assurance that the pandemic will not worsen again, included as a result of the emergence of new strains of the virus. There is still considerable uncertainty regarding the impact on our business stemming from current measures and potential future measures that could restrict access to our facilities, limit manufacturing and support operations and place restrictions on our workforce and suppliers. In February 2022, Russia began a military intervention in Ukraine. In response, global sanctions were imposed against Russia. These sanctions and the related global ramifications could impact the costs and timing of construction of the Origin 1 and Origin 2 plants including, for example, by increasing the cost of transportation or limiting the availability of certain materials of construction, such as metals used in alloys, that are sourced from Russia or Ukraine.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). Pursuant to the Merger Agreement, the merger between Merger Sub and Legacy Origin was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, Artius was treated as the “acquired” company and Legacy Origin was treated as the acquirer for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Legacy Origin issuing stock for the net assets of Artius, accompanied by a recapitalization. The net assets of Artius are stated at historical cost, with no goodwill or other intangible assets recorded. Legacy Origin was determined to be the accounting acquirer based on the following predominant factors: • the Company’s Board and management are primarily composed of individuals associated with Legacy Origin; • Legacy Origin’s senior management comprise the senior management roles of the Company and are responsible for the day-to-day operations; • the Company assumed the “doing business as” name of the Legacy Origin; and • The intended strategy and operations of the Company continue Legacy Origin’s current strategy and operations as a carbon negative materials company with a mission to enable the world’s transition to sustainable materials. The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of Legacy Origin. The shares and corresponding capital amounts and losses per share, prior to the Business Combination, have been retroactively restated based on shares reflecting the Exchange Ratio (as defined below) established in the Business Combination. Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, those related to the valuation of common stock and valuation of convertible preferred stock warrants prior to the Business Combination, valuation of the earnout liability, valuation of assumed common stock warrants liability, carrying amount and useful lives of property and equipment and intangible assets, impairment assessments, marketable securities, stock-based compensation expense, probabilities of achievement of performance conditions on performance stock awards, among others. The Company bases these estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. Principles of Consolidation The consolidated financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash, cash equivalents, and marketable securities accounts with a financial institution where, at times, deposits exceed federal insurance limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on these deposits. Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an initial maturity of three months or less at the date of purchase to be cash equivalents. The Company maintains such funds in cash deposits and money market accounts. Restricted cash consists of cash held in a control account as collateral for the Company’s credit card services, escrow services, and standby letter of credit. These restricted cash balances have been excluded from cash and cash equivalents balance and are included within other current assets in the Consolidated Balance Sheets based on the respective maturity dates. The Company entered into an escrow agreement on September 27, 2019 for $1.3 million, whereby the funds would be used for construction and transportation services in connection with Origin 1. At December 31, 2022 and 2021, the escrow account had a balance of $0.3 million. The Company has a standby letter of credit, whereby the funds may be used for the completion of work, services, and improvements in connection with Origin 1. The standby letter of credit matures and automatically renews in October of each year. At December 31, 2022 and 2021, the standby letter of credit was $0.2 million. Cash, cash equivalents, and restricted cash consisted of the following (in thousands): December 31, 2022 December 31, 2021 Cash and cash equivalents $ 107,858 $ 46,637 Restricted cash 490 490 Total cash, cash equivalents, and restricted cash $ 108,348 $ 47,127 Marketable Securities The Company’s investment policy requires the Company to purchase investments that meet the definition of available-for-sale securities. The Company does not buy and hold securities principally for the purpose of selling them in the near future. The Company’s policy is focused on the preservation of capital, liquidity, and return. The Company considers all of its marketable debt securities as available for use in current operations, including those with maturity dates beyond one year, and therefore classifies these securities within current assets on the consolidated balance sheets. Securities are classified as available for sale and are carried at fair value, with the change in unrealized gains and losses, net of tax, reported as a separate component on the consolidated statements of comprehensive income until realized. Fair value is determined based on quoted market rates when observable or utilizing data points that are observable, such as quoted prices, interest rates and yield curves. Securities with an amortized cost basis in excess of estimated fair value are assessed to determine what amount of the excess, if any, is caused by expected credit losses. Expected credit losses on securities are recognized in other income (expense), net on the consolidated statements of operations and comprehensive income (loss), and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in the consolidated statements of redeemable convertible preferred stock, stockholders' equity and accumulated other comprehensive income (loss). For the purposes of computing realized and unrealized gains and losses, the cost of securities sold is based on the specific-identification method. Interest on securities classified as available for sale is included as a component of interest income within other income (expense). The nature of these financial instruments include instruments for which quoted prices are available but traded less frequently, instruments whose fair value has been derived using a model where inputs to the model are directly observable in the market, or can be derived principally from or corroborated by observable market data, and instruments that are fair valued using other financial instruments, the parameters of which can be directly observed. Level 2 financial instruments include agency mortgage-backed securities, corporate fixed income securities infrequently traded, and other securities, which primarily consist of sovereign debt, U.S. government agency securities, loans, and state and municipal securities. Derivative Financial Instruments The Company evaluated the stockholder convertible notes payable in accordance with ASC 815, Derivatives and Hedging and determined that the embedded components of these contracts qualify as a derivative to be separately accounted for as a liability. The Company records the fair value of the embedded components in accordance with ASC 815, Derivatives and Hedging . The fair value of the derivatives was calculated using a model that estimated the value that would be paid to transfer the liability in an orderly transaction between market participants at the measurement date. The fair value of the derivative liabilities is revalued on each balance sheet date with a corresponding gain or loss recorded in the Consolidated Statements of Operations and Comprehensive Income (Loss). The Company enters into foreign currency derivative contracts with financial institutions to reduce foreign exchange risk related to marketable securities. The Company uses forward currency derivative contracts to minimize the Company’s exposure to balances primarily denominated in the British Pound Sterling and Australian Dollar. The Company’s foreign currency derivative contracts, which are not designated as hedging instruments, are used to reduce the exchange rate risk associated primarily with marketable securities. The Company’s derivative financial instruments program is not designated for trading or speculative purposes. Outstanding foreign currency derivative contracts are recorded at fair value on the consolidated balance sheets. Foreign currency derivative contracts are marked-to-market at the end of each reporting period with gains and losses recognized in the change in fair value of derivatives within other (income) expense. While the contract or notional amount is often used to express the volume of foreign currency derivative contracts, the amounts potentially subject to credit risk are generally limited to the amounts, if any, by which the counterparties’ obligations under the agreements exceed the obligations of the Company to the counterparties. The notional amount of foreign currency derivative contracts as of December 31, 2022 and 2021 was $21.2 million and $63.7 million, respectively. Fair Value of Financial Instruments The Company applies the fair value measurement accounting standard whenever other accounting pronouncements require or permit fair value measurements. Fair value is defined in the accounting standard as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy under current accounting guidance prioritizes the inputs to valuation techniques used to measure fair value into three broad levels (Level 1, Level 2, and Level 3). Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk) in a principal market. The carrying amounts of working capital balances approximate their fair values due to the short maturity of these items. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest rate, currency, or credit risks arising from its financial instruments. We have determined the fair value of debt approximates the carrying value due to the standard terms of the arrangement including but not limited to the amount borrowed, the term, and the interest rate. The fair values of the Assumed Common Stock Warrants which are publicly traded are level 1 inputs. The fair value of the Assumed Common Stock Warrants which are not publicly traded, cash equivalents, marketable securities, and foreign currency derivative contracts are level 2 inputs as the Company uses quoted market prices or alternative pricing sources and models utilizing observable market inputs. The earnout liability, derivative liability and redeemable convertible preferred stock warrant liability were estimated using Level 3 inputs. Other Receivables Other receivables consist of amounts due from foreign governmental entities related to the Canadian harmonized sales tax ("HST") and goods and services tax ("GST") for goods and services transacted in Canada, and amounts due from cash collateral held by others for foreign currency derivative contracts. AgriScience Grant In January 2019, the Company entered into an agreement in which it will participate in the AgriScience Program Cluster Component grant through the Canadian Agricultural Partnership, whereby the Company will receive reimbursements for eligible expenditures up to approximately $1.8 million (in Canadian dollars) through March 2023. Grants are received through reimbursements from the Canadian government and recognized, upon completion of scope of services on a quarterly basis. Grants are recognized as a reduction of property, plant, and equipment or expense based on the nature of the cost the grant is reimbursing. During the year ended December 31, 2022, 2021 and 2020 the Company received $0.4 million, $0.0 million and $0.2 million, respectively, in grants which recorded in other income. Property, Plant, and Equipment Property, plant, and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the respective assets. Existing useful lives range from 3 to 5 years. Leasehold improvements are amortized using the straight-line method over the shorter of their estimated useful lives or the lease term. Major additions and improvements are capitalized, while replacements, repairs, and maintenance that do not extend the life of an asset are charged to operations. We depreciate plants over a maximum life of 40 years and plant improvements over the shorter of the asset life or remaining useful life of the plants structure using the straight-line method. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts. Costs incurred to acquire, construct or install property, plant, and equipment during the construction stage of a capital project and costs capitalized in conjunction with major improvements that have not yet been placed in service are recorded as construction in progress, and accordingly are not currently being depreciated. The Company capitalizes interest cost incurred on funds used to construct property, plant and equipment. The estimated useful lives of assets are as follows: Computer and other equipment 3 years Pilot plant 5 years Machinery and equipment 5 years Leasehold improvements 1-5 years Plants and improvements 20-40 years Intangible Assets Intangible assets are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the respective assets, ranging from 7 to 15 years. The cost of servicing the Company’s patents is expensed as incurred. Upon retirement or sale, the cost of intangible assets is disposed of and the related accumulated amortization is removed from the accounts. Impairment of Long-Lived Assets The Company reviews its long-lived assets, including property, equipment, software and intangibles, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. If indicators of impairment exist, management identifies the asset group which includes the potentially impaired long-lived asset, at the lowest level at which there are separate, identifiable cash flows. If the total of the expected undiscounted future net cash flows for the asset group is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset. For the year ended December 31, 2022 and 2021, no impairment was identified. Government Loans Government loans are classified as a noncurrent liability and recorded at amortized cost. Forgiveness of the balances due is recorded through earnings and occurs when there is confirmation from the governmental authority that the Company has complied with the conditions for forgiveness attached to the loan. Debt Issuance Costs The costs incurred in connection with the issuance of debt obligations, principally financing and legal costs, are capitalized. These costs are accreted over the term of the debt using the interest method. During the year ended December 31, 2022, 2021 and 2020, accretion expense for debt issuance cost was zero, $2.2 million and $0.1 million, respectively. Redeemable Convertible Preferred Stock Warrants Liability Free-standing warrants issued by Legacy Origin for the purchase of shares of its convertible preferred stock were classified as liabilities on the accompanying balance sheets at fair value using an Option-Pricing Model. Prior to the Business Combination, the liability recorded was adjusted for changes in the fair value at each reporting date and recorded as interest expense in the accompanying Consolidated Statements of Operations and Comprehensive Income (Loss). As a result of the Business Combination, the Legacy Origin warrants each converted into a warrant to purchase shares of the Company’s Common Stock converted at the Exchange Ratio. The fair value of the warrants upon consummation of the Business Combination (see Note 4), is adjusted based on the price of the underlying Common Stock, was reclassified to additional paid-in capital. Assumed Common Stock Warrants Liability The Company assumed 24,149,960 public warrants (the “Public Warrants”) and 11,326,667 private placement warrants (the “Private Placement Warrants”, and the Public Warrants together with the Private Placement Warrants, the “Assumed Common Stock Warrants”) upon the Business Combination, all of which were issued in connection with Artius’ initial public offering and entitle each holder to purchase one share of Class A common stock at an exercise price of at $11.50 per share. As of December 31, 2022, 24,149,960 Public Warrants and 11,326,667 Private Placement Warrants are outstanding. The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the warrants may be cashless exercised. The Private Placement Warrants are transferable, assignable or salable in certain limited exceptions. The Private Placement Warrants are exercisable for cash or on a cashless basis, at the holder’s option, and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will cease to be Private Placement Warrants, and become Public Warrants and be redeemable by the Company and exercisable by such holders on the same basis as the other Public Warrants. The Company evaluated the Assumed Common Stock Warrants under ASC 815-40, Derivatives and Hedging-Contracts in Entity’s Own Equity (“ASC 815-40”) , and concluded they do not meet the criteria to be classified in stockholders’ equity. Specifically, the exercise of the Assumed Common Stock Warrants may be settled in cash upon the occurrence of a tender offer or exchange that involves 50% or more of our Class A stockholders. Because not all of the voting stockholders need to participate in such tender offer or exchange to trigger the potential cash settlement and the Company does not control the occurrence of such an event, the Company concluded that the Assumed Common Stock Warrants do not meet the conditions to be classified in equity. Since the Assumed Common Stock Warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as liabilities on the Consolidated Balance Sheets at fair value, with subsequent changes in their respective fair values recognized in the change in fair value of Assumed Common Stock Warrant liabilities within the Consolidated Statements of Operations and Comprehensive Income (Loss) at each reporting date. The Public Warrants were publicly traded and thus had an observable market price to estimate fair value, and the Private Placement Warrants were effectively valued similar to the Public Warrants, as described in Note 6. Earnout Liability The Company has recorded an earnout liability related to future contingent equity shares related to the Business Combination (Note 13). The Company recorded these instruments as liabilities on the Consolidated Balance Sheets at fair value, with subsequent changes in their respective fair values recognized in earnings at each reporting date. Leases The Company has leases for office space and equipment, some of which have escalating rentals during the initial lease term and during subsequent optional renewal periods. The Company accounts for its leases under ASC Topic 842, Leases . The Company recognizes a right-of-use asset and lease liability for leases based on the net present value of future minimum lease payments. Lease expense is recognized on a straight-line basis over the non-cancelable lease term and renewal periods that are considered reasonably certain to be exercised. Research and Development Cost Costs related to research and development are expensed as incurred. Stock-Based Compensation The Company has issued common stock awards under three equity incentive plans. Origin measures stock options and other stock-based awards granted to employees, directors and other service providers based on their fair value on the date of grant and recognizes compensation expenses of those awards over the requisite service period, which is generally the vesting period of the respective award. For awards with performance conditions, compensation is recorded once there is sufficient objective evidence the performance conditions are considered probable of being met. Origin applies the straight-line method of expense recognition to all awards with only service-based vesting conditions. Origin estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model and the grant date closing stock price for RSU awards and performance awards. The Black-Scholes option-pricing model requires the use of highly subjective assumptions including: • Expected term – The expected term of the options is based on the simplified method, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option which averages an award’s vesting term and its contractual term. • Expected volatility – The Company uses the trading history of various companies in its industry sector in determining an estimated volatility factor. • Expected dividend – The Company has not declared common stock dividends and does not anticipate declaring any common stock dividends in the foreseeable future. • Forfeiture – The Company estimates forfeitures based on historical activity and considers voluntary and involuntary termination behavior as well as analysis of actual historical option forfeitures, netting the estimated expense by the derived forfeiture rate. • Risk-free interest rate – The Company bases the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with the same or substantially equivalent remaining term. Income Taxes Deferred income taxes are determined using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when the expected recognition of a deferred income tax asset is considered to be unlikely. The Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company recognizes interest and penalties related to income tax matters as a component of income tax expense. Functional Currency Translation The functional currency of the Company’s wholly-owned Canadian subsidiaries is the Canadian dollar, whereby their assets and liabilities are translated at period-end exchange rates except for nonmonetary capital transactions and balances, which are translated at historical rates. All income and expense amounts of the Company are translated at average exchange rates for the respective period. Translation gains and losses are not included in determining net loss but are accumulated in a separate component of stockholders’ equity. Foreign currency transaction gains and losses are included in the determination of net loss in the period in which they occur. These amounts are included in other income, net, of the Consolidated Statements of Operations and Comprehensive Income (Loss). Comprehensive Income (Loss) The Company’s comprehensive income or loss consists of net income or loss and other comprehensive income (loss). Foreign currency translation gains or losses and unrealized gains or losses on available-for-sale marketable debt securities are included in the Company’s other comprehensive income (loss). Basic and Diluted Net Income (Loss) Per Share Basic net income (loss) per common share is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For the purposes of the diluted net income (loss) per share calculation, the convertible preferred stock, common stock options, RSU awards, performance stock awards, convertible preferred stock warrants, common stock warrants, convertible notes, earnout shares, and Sponsor Vesting Shares (as defined below) are considered to be potentially dilutive securities. Basic and diluted net income (loss) per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. All series of the Company’s convertible preferred stock are considered to be participating securities because, in addition to cumulative dividends, all holders are entitled to receive a non-cumulative dividend on a pari passu basis in the event that a dividend is paid on the common stock. The two-class method requires income or loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in undistributed earnings as if all income or loss for the period had been distributed. The holders of the convertible preferred stock do not have a contractual obligation to share in the Company’s losses. Accordingly, the Company’s net income (loss) is attributed entirely to common stockholders. For the periods presented that the Company has reported a net loss, diluted net loss per common share is the same as basic net loss per common share for those periods. Reclassifications Certain amounts in prior periods have been reclassified to conform with the report classifications of the year ended December 31, 2021, noting the Company has reflected the Reverse Recapitalization pursuant to the Business Combination for all periods presented within the Consolidated Balance Sheets and Consolidated Statements of Redeemable Convertible Preferred Stock, Stockholders’ Equity and Accumulated Other Comprehensive Income (Loss). Segment Reporting The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company has determined that its Co-Chief Executive Officers are the CODM. To date, the Company’s CODM has made such decisions and assessed performance at the Company level.

Business Combination

Business Combination	12 Months Ended
Business Combination	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Business Combination	Business Combination On June 25, 2021, Artius and Micromidas, Inc. (now known as Origin Materials Operating, Inc., “Legacy Origin”) completed the Business Combination pursuant to the Merger Agreement with Legacy Origin surviving the merger as a wholly owned subsidiary of Artius, which became Origin Materials, Inc. Cash proceeds from the Business Combination totaled approximately $467.5 million, which included funds held in Artius’s trust account and the completion of the concurrent PIPE and Backstop Financing. In accordance with the terms and subject to the conditions of the Merger Agreement, at the effective time of the Merger, (i) all shares of Legacy Origin’s Series A, Series B, and Series C Preferred Stock, and Common Stock (collectively, “Legacy Origin Stock”) issued and outstanding immediately prior to the effective time of the Merger were converted into the right to receive their pro rata portion of shares of Company Common Stock (the “Common Stock”) issued as Merger consideration (the “Merger Consideration”); (ii) holders of Legacy Origin’s Convertible Notes Payable, plus accrued interest also received shares of Company Common Stock; (iii) each option exercisable for Legacy Origin Stock that was outstanding immediately prior to effective time of the Merger was assumed and continues in full force and effect on the same terms and conditions as were previously applicable to such options, subject to adjustments to exercise price and number of shares Common Stock issuable upon exercise based on the final conversion ratio calculated in accordance with the Merger Agreement. Additionally, as part of the consideration transferred, stockholders of Legacy Origin and Artius were given the right to additional shares in the Company. These shares vest to the holder upon the share price of the Company reaching certain targets over a future period (“Earnout Shares”, see Note 13). The Company accounted for the Business Combination as the Reverse Recapitalization, which is the equivalent of Legacy Origin issuing stock for the net assets of Artius, accompanied by a recapitalization, with Artius treated as the acquired company for accounting purposes. The determination of Artius as the “acquired” company for accounting purposes was primarily based on the fact that subsequent to the Business Combination, Legacy Origin will comprise all of the ongoing operations of the combined entity, a majority of the governing body of the combined company and Legacy Origin’s senior management will comprise all of the senior management of the combined company. The net assets of Artius were stated at historical cost with no goodwill or other intangible assets recorded. Reported results from operations included herein prior to the Business Combination are those of Legacy Origin. The shares and corresponding capital amounts and loss per share related to Legacy Origin’s outstanding convertible preferred stock and common stock prior to the Business Combination have been retroactively restated to reflect the conversion ratio established in the Merger Agreement (1.00 Legacy Origin share for approximately 2.11 shares of the Company, the Exchange Ratio). In connection with the Business Combination, the Company incurred underwriting fees and other costs considered direct and incremental to the transaction totaling $36.7 million, consisting of legal, accounting, financial advisory and other professional fees. These amounts are reflected within additional paid-in capital in the Consolidated Balance Sheets as of December 31, 2022 and 2021. PIPE Financing Concurrent with the execution of the Business Combination, the Company entered into subscription agreements with certain investors (the “PIPE Investors”) pursuant to which the PIPE Investors subscribed for and purchased an aggregate of 20,000,000 shares of Common Stock for an aggregate purchase price of $200.0 million. Backstop Agreement Concurrent with the execution of the Business Combination, the Company entered into various subscription agreements (the “Subscription Agreements”) with certain current shareholders of the Company or their affiliates (collectively, the “Subscribers”), pursuant to which the Subscribers agreed, subject to certain conditions in the Subscription Agreements, to purchase an aggregate amount of 4,300,001 shares of common stock of the Company, par value $0.0001 per share (the “Subscription Shares”), at $10.00 per share. Summary of Net Proceeds The following table summarizes the elements of the net proceeds from the Business Combination at the date of acquisition (in thousands): Cash—Trust Account (net of redemptions of $439.0 million) $ 260,448 Cash 60 Cash—PIPE & Backstop Financing 243,000 Non-cash net assets assumed from Artius 40 Less: Fair value of assumed common stock warrants (83,370) Less: Underwriting fees and other issuance costs paid prior to the date of acquisition (34,773) Additional Paid-in-Capital from Business Combination, net of issuance costs paid $ 385,405 Less: Non-cash net assets assumed from Artius (40) Add: Non-cash fair value of assumed common stock warrants 83,370 Add: Other issuance costs included in accounts payable and accrued liabilities 761 Less: Accrued liabilities extinguished through proceeds from Business Combination (1,966) Cash proceeds from the Business Combination $ 467,530 Summary of Shares Issued The following table summarizes the number of shares of Common Stock outstanding immediately following the consummation of the Business Combination: Artius shares outstanding prior to the Business Combination, including 4,500,000 Sponsor Vesting Shares 90,562,500 Less: redemption of Artius shares (43,880,956) Shares issued pursuant to the PIPE and Backstop Financing 24,300,001 Business Combination and PIPE Financing shares, including 4,500,000 Sponsor Vesting Shares 70,981,545 Conversion of Legacy Origin Series A preferred stock for common stock 33,783,099 Conversion of Legacy Origin Series B preferred stock for common stock 19,755,784 Conversion of Legacy Origin Series C preferred stock for common stock 6,286,349 Conversion of Legacy Origin convertible notes for common stock 2,049,212 Conversion of Legacy Origin common stock for common stock 2,838,041 Issuance of common stock upon exercise of warrants 5,554,440 Total shares of the Company common stock outstanding immediately following the Business Combination 141,248,470

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
Recent Accounting Pronouncements	Dec. 31, 2022
Recent Accounting Pronouncements [Abstract]
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. The guidance is effective for fiscal years beginning on or after December 15, 2021, with early adoption permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted the new standard as of January 1, 2022. The adoption of the standard had no material impact on the Company’s financial results. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform ("Topic 848"): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , as amended and supplemented by subsequent ASUs (collectively, “ASU 2020-04”), which provides practical expedients for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. This guidance is applicable for borrowing instruments, which use LIBOR as a reference rate, and is effective immediately, but is only available through December 31, 2022. The Company adopted the new standard as of January 1, 2022. The adoption of the standard had no material impact on the Company’s financial results. In November 2021, the FASB issued ASU 2021-10, Government Assistance ("Topic 832"), Disclosures by Business Entities about Government Assistance . The FASB issued this update to increase the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements. The main provisions of this update require the following disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy: (i) Information about the nature of the transactions and the related accounting policy used to account for the transactions (ii) The line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item (iii) Significant terms and conditions of the transactions, including commitments and contingencies. The amendments in this update are effective for the Company in the annual period beginning after December 15, 2021. Early application of the amendments is permitted. The Company has elected to adopt on January 1, 2022. The adoption of the standard had no impact on the Company’s financial results. See Note 3 and Note 14 for required disclosures. Recently Issued Accounting Pronouncements Not Yet Adopted In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . This update improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to (1) recognition of an acquired contract liability; and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. Specifically, the update requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers . The amendments in this update are effective for the Company in the fiscal year beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted, including adoption in an interim period. The pronouncement is not expected to have a significant impact on the Company's consolidated financial statements. In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging ("Topic 815") ("ASU 2022-01"). This update clarifies the guidance in Topic 815 on fair value hedge accounting of interest rate risk for portfolios and financial assets. Among other things, the amended guidance established the “last-of-layer” method for making the fair value hedge accounting for these portfolios more accessible and renamed that method the “portfolio layer” method. ASU 2022-01 is effective January 1, 2023 and is not expected to have a significant impact on the Company's consolidated financial statements.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
Fair Value Measurement	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows: Fair Value as of December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Assets: Cash, cash equivalents and restricted cash $ 108,348 $ — $ — $ 108,348 Marketable securities — 215,464 — 215,464 Total fair value $ 108,348 $ 215,464 $ — $ 323,812 Liabilities: Assumed common stock warrants (Public) $ 21,015 $ — $ — $ 21,015 Assumed common stock warrants (Private Placement) — 9,856 — 9,856 Earnout liability — — 42,533 42,533 Derivative liability — 344 — 344 Total fair value $ 21,015 $ 10,200 $ 42,533 $ 73,748 Fair Value as of December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Assets: Cash, cash equivalents and restricted cash $ 47,127 $ — $ — $ 47,127 Marketable securities — 397,458 — 397,458 Derivative asset — 202 — 202 Total fair value $ 47,127 $ 397,660 $ — $ 444,787 Liabilities: Assumed common stock warrants (Public) $ 35,983 $ — $ — $ 35,983 Assumed common stock warrants (Private Placement) — 16,877 — 16,877 Earnout liability — — 127,757 127,757 Derivative liability — 103 — 103 Total fair value $ 35,983 $ 16,980 $ 127,757 $ 180,720 The Company performs routine procedures such as comparing prices obtained from independent sources to ensure that appropriate fair values are recorded. The marketable securities are categorized as Level 2 instruments as the estimated fair value was determined based on the estimated or actual bids and offers of the marketable securities in an over-the-counter market on the last business day of the period. All of the Company’s cash, cash equivalents, restricted cash, marketable securities and foreign currency derivative contracts are classified within Level 1 or Level 2 because the Company’s cash, cash equivalents, restricted cash, marketable securities and foreign currency derivative contracts are valued using quoted market prices or alternative pricing sources and models utilizing observable market inputs. Because the transfer of Private Placement Warrants to anyone outside of certain permitted transferees of Artius Acquisition Partners LLC (the “Sponsor”) would result in the Private Placement Warrants having substantially the same terms as the Public Warrants, the Company determined that the fair value of each Private Placement Warrant is consistent with that of a Public Warrant. Accordingly, the Private Placement Warrants are classified as Level 2 financial instruments. The value of the Earnout liability is classified as Level 3 measurements under the fair value hierarchy, as these liabilities have been valued based on significant inputs not observable in the market. As of December 31, 2022 and 2021, the carrying values of cash and cash equivalents, accounts payable and accrued liabilities approximate their respective fair values due to their short-term nature. Marketable Securities The Company’s marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. Amortized cost net of unrealized gain (loss) is equal to fair value. The following table summarized the marketable securities by major security type as follows: As of December 31, 2022 (in thousands) Investments Classified as Marketable Securities Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper $ 17,568 $ 38 $ — $ 17,606 Corporate bonds 115,134 — (4,923) 110,211 Asset-backed securities 70,825 8 (3,885) 66,948 U.S. government and agency securities 19,308 — (917) 18,391 Foreign government and agency securities 375 — (37) 338 Municipal/provincial bonds and other 2,000 — (30) 1,970 Total marketable securities $ 225,210 $ 46 $ (9,792) $ 215,464 As of December 31, 2021 (in thousands) Investments Classified as Marketable Securities Amortized Cost Unrealized Gains Unrealized Losses Fair Value Corporate bonds $ 274,939 $ 100 $ (1,725) $ 273,314 Asset-backed securities 96,713 190 (199) 96,704 U.S. government and agency securities 20,235 — (64) 20,171 Foreign government and agency securities 3,262 — (19) 3,243 Municipal/provincial bonds and other 4,000 5 — 4,005 Total $ 399,149 $ 295 $ (2,007) $ 397,437 Pending purchases and sales 21 — — 21 Total marketable securities $ 399,170 $ 295 $ (2,007) $ 397,458 Any realized gains and losses and interest income are included in other income on the Consolidated Statements of Operations and Comprehensive Income (Loss). We sold marketable securities for proceeds of $3,815.9 million, $2,024.1 million and zero during the year ended December 31, 2022, 2021 and 2020, respectively. As a result of those sales, we realized a loss of $1.0 million, a gain of $0.2 million, and zero during the year ended December 31, 2022, 2021 and 2020, respectively. We regularly review our available-for-sale marketable securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The aggregate fair value of the marketable securities in unrealized loss position was $193.5 million and $346.3 million as of December 31, 2022 and 2021, respectively. The unrealized losses were attributable to changes in interest rates that impacted the value of the investments, and not related to increased credit risk. Accordingly, we have not recorded an allowance for credit losses associated with these investments. The contractual maturities of the investments classified as marketable securities are as follows: As of December 31, 2022 (in thousands) Mature within one year Mature after one year through two years Mature over two years Fair Value Commercial paper $ 17,606 $ — $ — $ 17,606 Corporate bonds 74,797 35,414 — 110,211 Asset-backed securities 1,907 4,833 60,207 66,947 U.S. government and agency securities 7,719 7,480 3,192 18,391 Foreign government and agency securities — 338 — 338 Municipal/provincial bonds and other 1,971 — — 1,971 Total marketable securities $ 104,000 $ 48,065 $ 63,399 $ 215,464 As of December 31, 2021 (in thousands) Mature within one year Mature after one year through two years Mature over two years Fair Value Corporate bonds $ 92,559 $ 134,199 $ 46,556 $ 273,314 Asset-backed securities — 2,000 94,704 96,704 U.S. government and agency securities — 7,995 12,176 20,171 Foreign government and agency securities 2,877 — 366 3,243 Municipal/provincial bonds and other 2,002 2,003 — 4,005 Total $ 97,438 $ 146,197 $ 153,802 $ 397,437 Pending purchases and sales 21 — — 21 Total marketable securities $ 97,459 $ 146,197 $ 153,802 $ 397,458 Redeemable Convertible Preferred Stock Warrant Liability Free-standing warrants issued by Legacy Origin for the purchase of shares of its convertible preferred stock were classified as liabilities on the accompanying balance sheets at fair value using an Option-Pricing Model (“OPM”). Prior to the Business Combination, the liability recorded was adjusted for changes in the fair value at each reporting date and recorded as interest expense in the accompanying Consolidated Statements of Operations and Comprehensive Income (Loss). As a result of the Business Combination, the Legacy Origin warrants each converted into common stock of Origin at the Exchange Ratio defined in the Merger Agreement. Derivative Asset and Liabilities Beginning in the year ended December 31, 2021, the Company entered into foreign currency derivative contracts with financial institutions to reduce foreign exchange risk related to certain marketable securities denominated in foreign currency. Foreign currency derivative contracts are marked-to-market at the end of each reporting period with gains and losses recognized as other income (expense). During the year ended December 31, 2022 and 2021, the Company recognized a net loss of $0.4 million and a net gain of $0.1 million, respectively, on the fair value adjustment of the foreign currency derivative contracts. The following table sets forth a summary of the activities of the Company’s redeemable convertible preferred stock warrant liability and embedded components of the stockholder convertible notes payable, which represents a recurring measurement that is classified within Level 3 of the fair value hierarchy wherein fair value is estimated using significant unobservable inputs: Redeemable Convertible Preferred Stock Warrant Years Ended December 31, (in thousands) 2022 2021 Beginning warrant liability balance $ — $ 19,233 Change in fair value of warrants liability — 35,034 Reclassification to APIC upon recapitalization — (54,267) Ending warrant liability balance $ — $ — Embedded Derivative - Stockholder Convertible Notes Payable Years Ended December 31, (in thousands) 2022 2021 Beginning derivative liabilities balance $ — $ 1,238 Change in fair value — (1,238) Ending derivative liabilities balance $ — $ —

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
Property, Plant and Equipment	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant, and equipment consisted of the following: (in thousands) December 31, 2022 December 31, 2021 Land $ 11,358 $ 912 Pilot plant 4,599 5,517 Lab equipment 2,526 2,227 Machinery and equipment 948 655 Computer and other equipment 598 388 Construction in process 138,847 55,026 Total 158,876 64,725 Less accumulated depreciation and amortization (4,693) (7,540) Total property, plant, and equipment, net $ 154,183 $ 57,185 For the year ended December 31, 2022, 2021 and 2020, depreciation expense totaled $0.7 million, $0.5 million and $0.5 million, respectively. At December 31, 2022 and 2021, the Company capitalized $1.1 million and $0.9 million, respectively, of interest cost into Origin 1. At December 31, 2022 and 2021, the Company capitalized $1.9 million and $0.9 million of stock-based compensation related to employees whose costs are necessarily incurred to bring the asset to its intended use. At December 31, 2022 and 2021 a cumulative translation adjustment of $3.0 million and $(0.1) million, respectively, is included in total property, plant, and equipment as a result of foreign currency transaction gains and losses.

Intangible Assets

Intangible Assets	12 Months Ended
Intangible Assets	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets consisted of the following: (in thousands) December 31, 2022 December 31, 2021 Patents $ 404 $ 432 Less accumulated amortization (244) (217) Total intangible assets $ 160 $ 215

Consortium Agreement

Consortium Agreement	12 Months Ended
Consortium Agreement	Dec. 31, 2022
Transfers and Servicing [Abstract]
Consortium Agreement	Consortium Agreement The Company entered into consortium agreements with counterparties to collaborate on development of a process to commercialize bio-based, decarbonizing materials for application on an industrial scale at a competitive price. The agreements expire once performance of the research and development program has been completed. At the time the consortium agreements were entered into, several of the counterparties were related parties (Note 11). In 2020, an additional counterparty, that is not a related party, was added to the consortium agreement. Under the consortium agreement, the Company received zero, $0.5 million and $0.6 million during the year ended December 31, 2022, 2021 and 2020, respectively, which was recorded as other income, net in the Consolidated Statements of Operations and Comprehensive Income (Loss).

PPP Loan

PPP Loan	12 Months Ended
PPP Loan	Dec. 31, 2022
Debt Disclosure [Abstract]
PPP Loan	PPP Loan In April 2020, the Company executed a promissory note (the “PPP Note”) evidencing an unsecured loan in the amount of $0.9 million under the PPP Loan. The Paycheck Protection Program (or “PPP”) was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (“SBA”). The PPP Loan has been made through First Republic Bank (the “Lender”). The PPP Loan had a two-year term and bore interest at a rate of 1.00% per annum, accruing upon funding. Unless the PPP Loan is forgiven, the Company was required to make monthly payments of principal and interest to the Lender. The Company did not intend to seek forgiveness of the PPP loan. The PPP Note contained customary events of default relating to, among other things, payment defaults, providing materially false and misleading representations to the SBA or Lender, or breaching the terms of the PPP Loan documents. The occurrence of an event of default may result in the immediate repayment of all amounts outstanding, collection of all amounts owing from the Company, or filing suit and obtaining judgment.

Related Party Transactions

Related Party Transactions	12 Months Ended
Related Party Transactions	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions Consortium Agreements In December 2016, the Company entered into a consortium agreement (Note 9) with two Legacy Origin Series B preferred stock investors to collaborate on development of a process to commercialize bio-based, decarbonizing materials for application on an industrial scale at a competitive price. Under the consortium agreement, the Company received $0.5 million. The agreement expires once performance of the research and development program has been completed. In August 2018, the agreement was amended, whereby a Legacy Origin Series C preferred stock investor (the “Legacy Origin Series C Investor”, and collectively with the two Legacy Origin Series B investors, the “Legacy Origin Investors”) was added to the agreement and committed to invest $1.5 million of research and development in the consortium. As of December 31, 2022, the Legacy Origin Series C Investor had not invested any funds in the consortium. Offtake Agreements The Company maintains eight separate offtake supply agreements including five with Legacy Origin stockholders or affiliates of Legacy Origin stockholders (the “Offtake Agreements”). Two of the eight offtake agreements are with the same customer and pertain to supply of product from Origin 1 and Origin 2, respectively. Pursuant to the Offtake Agreements, the Company will construct manufacturing plants with specific capacity and product quality requirements within certain timeframes for the manufacture of product for sale to the counterparties to the agreements, and the counterparties will make minimum annual purchases at a set price, subject to adjustments, all as defined in the agreements. Our Offtake Agreements with two customers, who are Legacy Origin stockholders, allowed those customers to terminate the agreements and seek liquidated damages if specified construction and product delivery requirements are not satisfied. One of those Offtake Agreements has been amended to eliminate these construction and product delivery requirements and the associated liquidated damages provisions. On August 1, 2022, the Company amended its Offtake Agreement and related secured promissory note with one of its customers who is a Legacy Origin stockholder. The amendment converted the customer's obligation to purchase a specified annual amount of product from Origin 1 into an option to make a one-time purchase from Origin 1 and eliminated certain construction and delivery milestones and associated liquidated damages provisions applicable in the event those milestones were not met. In addition, the amendment reflected the customer's exercise of its option to enter into a new Offtake Agreement to buy a specified annual amount of product from Origin 2 for an initial term of up to 10 years. The related promissory note was amended to make each of three fixed repayments three months earlier and to allow the customer to offset amounts due under the amended Offtake Agreement against amounts owed under the amended note. The other Offtake Agreement continues to allow the customer to terminate the agreement and seek liquidated damages if specified requirements are not satisfied. For example, under the agreement, if Origin 1 had not commenced commercial operation by December 31, 2021 or we had not delivered specified product volume from Origin 1 by September 30, 2022, then we could be required to pay liquidated damages up to an aggregate of $0.2 million. The customer may also terminate the agreement and any outstanding secured promissory note resulting from an advance payment made to us by that customer will become due immediately. The outstanding obligations under that promissory note, together with accrued interest, totaled an aggregate of $5.4 million and $5.2 million as of December 31, 2022 and 2021, respectively. The Company believes enforcement of the liquidated damages provision under the foregoing Offtake Agreement is not probable and expects to secure amendments to this Offtake Agreement pursuant to its ongoing discussions with the customer. However, the Company cannot guarantee that it will be successful in amending this Offtake Agreement. Stockholder Convertible Notes Payable In November 2019, the Company entered into secured convertible note agreements (“Bridge Notes”) with certain Legacy Origin preferred stockholders, whereby the Company can borrow up to $6.0 million. The Bridge Notes bore an annual interest rate of 10% and matured on March 31, 2021, unless converted. If the Company issues shares of a new series of preferred stock prior to maturity, the outstanding principal and unpaid accrued interest will convert at 70% of the per share price of the new series of preferred stock. Upon a liquidation event, as defined in the agreements, the Company would be required to repay purchasers in cash an amount equal to 200% of the outstanding principal amount plus the outstanding principal and accrued interest. The Bridge Notes were collateralized by substantially all of the Company’s assets. The conversion and liquidation features were deemed to be derivatives under ASC 815 (see Note 6) and separately measured and recognized from the Bridge Notes through a debt discount. In January 2021, the Company amended the Bridge Notes to extend the maturity date from March 31, 2021 to September 30, 2021. The amendment also added a SPAC transaction to the conversion provision such that the Bridge Notes convert if the Company issues at least $50 million of shares of a new series of preferred stock or closes a SPAC transaction (each a “Qualified Financing”) prior to maturity. In a Qualified Financing that is a preferred stock issuance, the notes convert at 70% of the cash price paid per share for the preferred shares. In a Qualified Financing that is a SPAC transaction, the notes convert at the lesser of (i) 70% of the per share value attributed to the shares of the Company’s common stock as set forth in the Merger Agreement or (ii) the per share value that would be attributed to the Company’s common stock assuming a pre-transaction valuation of the Company in connection with the SPAC transaction of $700 million. These notes fully converted into the Company common stock upon consummation of the Business Combination (see Note 4). In February 2021 the Company issued $10.0 million of new, unsecured convertible notes (the “Convertible Notes”). The Convertible Notes bore an annual interest rate of 8% and mature on September 30, 2021, unless converted. If the Company issues at least $50 million worth of shares of a new series of preferred stock prior to maturity or closes a SPAC transaction (each a “Qualified Financing”), the outstanding principal and unpaid accrued interest will convert at 80% of the per share price of the new series of preferred stock or, in the case of a SPAC transaction, at 80% of the per share value attributed to the shares of the Company’s common stock as set forth in the Merger Agreement. Upon a Change of Control (other than a Qualified Financing), as defined in the Convertible Notes, the Company will repay purchasers in cash an amount equal to the outstanding principal and accrued interest plus a repayment premium equal to 100% of the outstanding principal amount of the notes. Debt issuance costs are recorded against the outstanding payable balance. These notes fully converted into the Company common stock upon consummation of the Business Combination (see Note 4). Legacy Stockholder Note In November 2016, the Company received a $5.0 million prepayment from a Legacy Origin stockholder for product from Origin 1 pursuant to an Offtake Agreement. The prepayment was to be credited against the purchase of products over the term of the Offtake Agreement. The prepayment was secured by a promissory note (the “Promissory Note”) to be repaid in cash in the event that the prepayment could not be credited against the purchase of product, for example, if Origin 1 was never constructed. The Promissory Note was collateralized substantially by Origin 1 and other assets of Origin Materials Canada Pioneer Limited. In May 2019, the Company and legacy stockholder amended the Offtake Agreement and Promissory Note. The amendment added accrued interest of $0.2 million to the principal balance of the prepayment and provided for the prepayment amount to be repaid in three annual installments rather than being applied against the purchase of product from Origin 1. On August 1, 2022, the Company and legacy stockholder further amended and restated the Promissory Note with an aggregate principal amount of $5.2 million which is the sum of the original principal with accrued interest prior to the amendment. As a result, the repayment dates were revised and to allow the Legacy Origin stockholder to offset amounts owed for the purchase of product from the Company's Origin 1 facility against amounts due under the Promissory Note. The repayment in the amount of $2.7 million is due on September 1, 2024, $1.9 million is due on September 1, 2025, and $1.8 million is due on September 1, 2026 (inclusive of accrued but unpaid interest). At December 31, 2022 and 2021, the total debt principal outstanding was $5.2 million. Legacy Related Party Other Liabilities, Long-term In November 2016, the Company received a $5.0 million prepayment from a Legacy Origin stockholder for product from Origin 1 pursuant to an Offtake Agreement. The prepayment is to be credited against the purchase of products from Origin 1 over the term of the Offtake Agreement. Specifically, repayment is effected by applying a credit to product purchases each month over the first five years of operation of Origin 1 up to $7.5 million, which is equal to 150% of the prepayment amount. If product purchases are not sufficient to recover the advances, the application of the credit to purchases as payment of the advances will continue until fully repaid. The prepayment is secured by a note to be repaid in cash in the event the prepayment cannot be credited against the purchase of product, for example, if Origin 1 is never constructed. The note is collateralized substantially by Origin 1 and other assets of Origin Materials Canada Pioneer Limited. If repaid in cash, the note bears an annual interest rate of the three-month London Interbank Offered Rate ("LIBOR") plus 0.25% (5.02% at December 31, 2022) and matures five years from the commercial operation date of Origin 1. At December 31, 2022 and 2021 the total note principal outstanding was $5.1 million and accrued interest outstanding was $0.3 million and $0.1 million, respectively.

Other Liabilities, Long-term

Other Liabilities, Long-term	12 Months Ended
Other Liabilities, Long-term	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
Other Liabilities, Long-term	Other Liabilities, Long-termIn September 2019, the Company entered into a $5.0 million prepayment agreement with a counterparty for the purchase of products from Origin 2. The prepayment is to be made in two equal installments: the first $2.5 million was in October 2019 and the remaining $2.5 million is due within 30 days of the customer confirming that a sample from Origin 1 meets the customer’s specifications. The Company and customer agreed to work in good faith to execute an Offtake Agreement, the agreed terms of which are set forth in the prepayment agreement, whereby 100% of the prepayment will be applied against future purchases. The prepayment agreement provides the customer a capacity reservation of up to a specified annual volume of product from Origin 1 for a term of ten years, pursuant to the terms of an Offtake Agreement. At December 31, 2022 and 2021, the total amount outstanding on this agreement was $2.5 million.

Earnout Liability

Earnout Liability	12 Months Ended
Earnout Liability	Dec. 31, 2022
Earnout Liability Disclosure [Abstract]
Earnout Liability	Earnout LiabilityAs additional consideration for the Merger, within ten (10) Business Days after the occurrence of a Triggering Event, the Company shall issue or cause to be issued to each Legacy Origin stockholder the number of shares of the Company Class A Common Stock equal to the product of (i) the number of shares of Company Common Stock, Company Series A Preferred Stock, Company Series B Preferred Stock, Company Series C Preferred Stock, and the net number of shares of Company Capital Stock that would be issuable in respect of Vested Company Options in the event such options were exercised (on a net exercise basis with respect to only the applicable exercise price, immediately prior to the Closing and settled in the applicable number of shares of Company Common Stock, rounded down to the nearest whole share) held by such Legacy Origin stockholder as of immediately prior to the Effective Time; and (ii) the Earnout Exchange Ratio (such issued shares of Artius Class A Common Stock, collectively, the “Earnout Shares”). Notwithstanding anything to the contrary herein, in no event shall Artius be required to issue more than 25,000,000 Earnout Shares in the aggregate. A Triggering Event is defined as the following: (a) the volume weighted average price of Common Stock ("VWAP") equaling on exceeding $15.00 for ten (b) the VWAP equaling or exceeding $20.00 for ten (c) the VWAP equaling or exceeding $25.00 for ten A Sponsor Letter Agreement was delivered in connection with the Merger such that 4.5 million of the shares held by Sponsor (“Sponsor Vesting Shares”) shall be subject forfeiture based on the same vesting requirements as the Earnout Shares. These shares shall not be transferred prior to the date in which they vest. Dividends and other distributions with respect to Sponsor Vesting Shares shall be set aside by the Company and shall be paid to the Sponsor upon the vesting of such Sponsor Vesting Shares. The Company evaluated the Earnout Liability under ASC 815-40, Derivatives and Hedging-Contracts in Entity’s Own Equity (“ASC 815-40”) , and concluded they do not meet the criteria to be classified in stockholders’ equity. Specifically, there are contingent exercise provisions and settlement provisions that exist. Holders may receive differing amounts of shares depending on the company’s stock price or the price paid in a change of control. It is noted that all remaining shares would be issuable (or the forfeiture provisions would lapse) upon any change of control involving the company and all remaining shares would be issuable (or the forfeiture provisions would lapse) upon a bankruptcy or insolvency of the company. This means that settlement is not solely impacted by the share price of the Company (that is, the share price observed in or implied by a qualifying change-in-control event), but also by the occurrence of a qualifying change-in-control event. This causes the arrangement to not be indexed to the Company’s own shares and liability classification is appropriate. The Company recorded these instruments as liabilities on the consolidated balance sheets at fair value, with subsequent changes in their respective fair values recognized in earnings at each reporting date. The earnout liability was fair valued using a Monte Carlo open-ended model. The inputs used for the model were a dividend yield of 0%, volatility of 70%, and interest rate of 4.08%. At December 31, 2022 and 2021 the balance of the earnout liability was $42.5 million and $127.8 million, respectively. A gain of $85.4 million and $75.5 million for the year ended December 31, 2022 and 2021, respectively, was recorded on the Consolidated Statement of Operations and Comprehensive Income (Loss) in the change in the fair value of earnout liability.

Canadian Government Research an

Canadian Government Research and Development Program Liability	12 Months Ended
	Dec. 31, 2022
Research and Development [Abstract]
Canadian Government Research and Development Program Liability	Canadian Government Research and Development Program Liability In April 2019, the Company entered into a contribution agreement related to the research and development and construction associated with the operation of Origin 1 in which the Company will participate in a Canadian government research and development program (the “R&D Agreement”). Pursuant to the R&D Agreement, the Company will receive funding for eligible expenditures through March 31, 2023 up to the lesser of approximately 18.48% of eligible costs and $23.0 million (in Canadian dollars). The funding will be repaid over 15 years after completion of Origin 1, commencing no sooner than the third fiscal year of consecutive revenues from a commercial plant, but no later than the fifth year following the earlier of (1) the year in which the Company completes construction of Origin 1 or (2) March 2023. The maximum amount to be repaid by the Company under the R&D Agreement is 1.25 times the actual funding received, subject to the following repayment ceiling formula. Repayment of the funding will be reduced by 50% if the Company begins construction before December 31, 2024 of one or more commercial plants that operate in Canada, with costs exceeding $500.0 million (in Canadian dollars), and the plants being constructed and operational within 30 months of the final investment decision, as defined in the R&D Agreement. Once begun, repayments will be paid annually by April of each year through March 31, 2037. Payments will be determined by a formula of the funded amount based on the fiscal year gross business revenue, as defined in the R&D Agreement. At December 31, 2022 and 2021, the Company recorded a liability for the amount received of $7.2 million and $6.8 million, respectively, on the Consolidated Balance Sheets in Canadian government research and development program liability.

Assumed Common Stock Warrants

Assumed Common Stock Warrants	12 Months Ended
Assumed Common Stock Warrants	Dec. 31, 2022
Assumed Common Stock Warrants [Abstract]
Assumed Common Stock Warrants	Assumed Common Stock Warrants As of December 31, 2022 and 2021, there are 35,476,627 warrants outstanding. As part of Artius’s initial public offering, 24,149,960 Public Warrants were sold. The Public Warrants entitle the holder thereof to purchase one share of Common Stock at a price of $11.50 per share, subject to adjustments. The Public Warrants may be exercised only for a whole number of shares of Common Stock. No fractional shares will be issued upon exercise of the warrants. The Public Warrants will expire on June 25, 2026 at 5:00p.m., New York City time, or earlier upon redemption or liquidation. The Public Warrants are listed on the Nasdaq under the symbol “ORGNW”. The Company may redeem the Public Warrants when exercisable, in whole and not in part, at a price of $0.01 per warrant, so long as the Company provides not less than 30 days’ prior written notice of redemption to each warrant holder, and if, and only if, the reported last sale price of the Common Stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date the Company sends the notice of redemption to the warrant holders. Simultaneously with Artius’s initial public offering, Artius consummated a private placement of 11,326,667 Private Placement Warrants with the Sponsor. The Private Placement Warrant is exercisable for one share of Class A Common Stock at a price of $11.50 per share, subject to adjustment. The Private Placement Warrants are identical to the Public Warrants, except that: (1) the Private Placement Warrants and the shares of Class A Common Stock issuable upon exercise of the Private Placement Warrants are not transferable, assignable or salable until the earliest to occur of: (i) 365 days after the date of the Closing; (ii) the first day after the date on which the closing price of the Public Shares (or any successor securities thereto) equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the date of the Closing; or (iii) the date on which Artius completes a liquidation, merger, capital stock exchange, reorganization or other similar transaction that results in all of Artius’s Public Shareholders having the right to exchange their Public Shares (or any successor securities thereto) for cash, securities or other property, subject to certain limited exceptions, (2) the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable, except if the reference value equals or exceeds $10.00 and is less than $18.00 (as described above), so long as they are held by the initial purchasers or their permitted transferees, and (3) the Private Placement Warrants and the Class A ordinary shares issuable upon exercise of the Private Placement Warrants will be entitled to registration rights. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable under all redemption scenarios by the Company and exercisable by such holders on the same basis as the Public Warrants. The Company concluded the Public Warrants and Private Placement Warrants, or Assumed Common Stock Warrants, meet the definition of a derivative under ASC 815 and are recorded as liabilities. Upon consummation of the Business Combination, the fair value of the Assumed Common Stock Warrants was recorded on the Consolidated Balance Sheets. The fair value of the Assumed Common Stock Warrants was remeasured on the December 31, 2022 and 2021 Consolidated Balance Sheets at $30.9 million and $52.9 million, respectively, and a gain of $22.0 million and $30.5 million, respectively, was recorded on the Consolidated Statement of Operations and Comprehensive Income (Loss).

Stockholders' Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity As of December 31, 2022 and 2021, 1,010,000,000 shares, $0.0001 par value per share are authorized, of which, 1,000,000,000 shares are designated as Common Stock and 10,000,000 shares are designated as Preferred Stock. Common Stock Holders of the Common Stock are entitled to dividends when, as, and if, declared by the Board, subject to the rights of the holders of all classes of stock outstanding having priority rights to dividends. As of December 31, 2022, the Company had not declared any dividends. The holder of each share of Common Stock is entitled to one vote. There were 143,034,225 and 141,301,569 shares of Common Stock (including 4,500,000 Sponsor Vesting Shares not indexed to equity) outstanding as of December 31, 2022 and December 31, 2021, respectively. Employee Stock Purchase Plan The Company maintains an Employee Stock Purchase Plan ("ESPP"). The ESPP permits participants to purchase shares of our Common Stock with the purchase price of the shares at a price determined by our board, which shall not be less than 85% of the lower of the fair market value of our Common Stock on the first day of an offering or on the date of purchase. Initially, following adoption of the ESPP, the maximum number of shares of our Common Stock that may be issued under the ESPP was 1,846,710 . The ESPP contains an “evergreen” share reserve feature that automatically increases the number of shares of Common Stock reserved for issuance under the plan on January 1 of each year for a period of ten years commencing on January 1, 2022 and ending on (and including) January 1, 2031 in an amount equal to the lesser of (1) one percent (1%) of the fully-diluted shares of our Common Stock on December 31st of the preceding calendar year, (2) 3,693,420 of Common Stock, or (3) such lesser number of shares as determined by our board of directors. On January 1, 2022, the number of shares of Common Stock reserved for issuance under the ESPP was automatically increased by 1,875,780 . As a result, as of December 31, 2022, the number of shares available for issuance under the ESPP was 3,722,490 . Shares subject to purchase rights granted under the ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the ESPP. To date no stock has been offered or issued to employee under the ESPP. Equity Incentive Plans The Company maintains the following equity incentive plans: the 2010 Stock Incentive Plan, the 2020 Equity Incentive Plan, and the 2021 Equity Incentive Plan, each as amended (together, the “Stock Plans”). Upon closing of the Business Combination, awards under the 2010 Stock Incentive Plan and 2020 Equity Incentive Plan were converted at the Exchange Ratio and the 2021 Equity Incentive Plan was adopted and approved. Origin may grant a wide variety of equity securities under the Stock Plans, including incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance-based stock awards, and other awards. The Company has granted incentive stock options, RSU awards, and performance awards under the Stock Plans. Under the Stock Plans, options must be issued at exercise prices no less than the estimated fair value of the stock on the date of grant and are exercisable for a period not exceeding 10 years from the date of grant. Options granted to employees under the Stock Plans generally vest 25% one year from the vesting commencement date and 1/36th per month thereafter, although certain arrangements call for vesting over other periods. Options granted to non-employees under the Stock Plan vest over periods determined by the Board (generally immediate to four years). RSU awards granted to employees under the 2021 Equity Incentive Plan require a service period of three years and generally vest 33.3% annually over the three-year service period. Under the Stock Plans, the fair value of RSU awards and performance-based stock awards are determined to be the grant date closing stock price. For awards with performance-based conditions, compensation is recorded once there is sufficient objective evidence the performance conditions are considered probable of being met. The performance-based stock awards are subject to vesting based on a performance-based condition and a service-based condition. The performance-based stock awards will vest in a percentage of the target number of shares between 0% and 300%, depending on the extent the performance conditions are achieved. Initially, following adoption of the 2021 Equity Incentive Plan, there were 18,467,109 shares of Common Stock reserved for issuance under the Stock Plans. The 2021 Equity Incentive Plan contains an “evergreen” share reserve feature that automatically increases the number of shares of Common Stock reserved for issuance under the plan on January 1 of each year for a period of ten years commencing on January 1, 2022 and ending on (and including) January 1, 2031 in an amount equal to five percent (5%) of the fully-diluted Common Stock on December 31 of the preceding year unless our board acts prior to January 1 to increase the share reserve by a lesser amount. The number of shares added to the share reserve on January 1 of a given year is reduced automatically to the extent necessary to avoid causing the share reserve to exceed fifteen percent (15%) of the fully-diluted Common Stock on December 31 of the preceding year. On January 1, 2022, the number of shares of Common Stock reserved for issuance under the 2021 Equity Incentive Plan was automatically increased by 9,378,902 shares pursuant to the 2021 Plan’s “evergreen” provision. As of December 31, 2022, there were 27,846,011 shares of common stock reserved under the Stock Plans. The following tables summarize stock option activity under the Stock Plans: Outstanding Options Weighted Weighted Average Balance as of December 31, 2020 8,222,710 $ 0.19 8.30 Granted — — Exercised (171,118) 0.42 Forfeited / canceled (158,735) 0.14 Balance as of December 31, 2021 7,892,857 $ 0.19 7.31 Granted — $ — Exercised (1,412,226) 0.28 Forfeited / canceled (9,569) 0.63 Balance as of December 31, 2022 6,471,062 $ 0.17 7.29 Vested and expected to vest at December 31, 2022 6,471,062 During the year ended December 31, 2022 and 2021, the Company did not grant any stock options. As of December 31, 2022 and 2021, there were 15,728,837 and 11,285,104 awards, respectively, available for grant under the Stock Plans. As of December 31, 2022 and 2021 there were 3,588,523 and 4,130,184 exercisable options, respectively. The total intrinsic value of the options exercised during 2022 and 2021 was $8.5 million and $0.3 million, respectively. The intrinsic value of options exercised during each fiscal year is calculated as the difference between the market value of the stock at the time of exercise and the exercise price of the stock option. The aggregate intrinsic value of options vested and expected to vest at December 31, 2022 and 2021 were $28.7 million and $49.3 million, respectively. As of December 31, 2022 and 2021, the Company had stock-based compensation of $4.7 million and $6.6 million respectively, related to unvested stock options not yet recognized that are expected to be recognized over an estimated weighted average period of 1.7 years and 2.6 years, respectively. The Company issued 2,920,732 of performance and market-based stock options during 2020. During the quarter ended March 31, 2021, the Company modified the vesting schedule of 529,119 of these performance and market based stock options such that vesting at 1/48th per month would commence upon signing of the Business Combination. The Company entered into the Merger Agreement on February 16, 2021 resulting in the commencement of expense recognition related to these 529,119 options during the quarter ended March 31, 2021. During the year ended December 31, 2021, stock compensation expense related to these performance and market based stock options was $2.9 million. For the remaining 2,391,613 performance and market-based stock options, expense commenced on the close date of the Merger, June 25, 2021, as that is the date when the performance condition was achieved. The following table summarizes the RSU award and performance-based stock award activity for the December 31, 2022 and 2021: Outstanding Weighted-average grant date fair value Unvested balance at December 31, 2020 — $ — Granted - RSU awards 769,505 7.34 Granted - performance-based stock awards 2,137,500 7.35 Unvested balance at December 31, 2021 2,907,005 $ 7.35 Granted - RSU awards 3,740,946 5.58 Granted - performance-based stock awards 505,500 5.69 RSU awards vested and converted to shares (320,430) 7.34 Vested - performance-based stock awards (391,575) 7.04 Forfeited - RSU awards (36,996) 6.07 Forfeited - performance-based stock awards (32,500) 6.23 Unvested balance at December 31, 2022 6,371,950 $ 6.24 Expected to vest 4,153,025 The RSU awards, which upon vesting entitles the holder to be issued on a future date the number of shares of Common S tock that is equal to the number of restricted stock units subject to the RSU awards. The total fair value of shares vested during 2022 and 2021 was $3.6 million and zero, respectively. As of December 31, 2022, one performance condition for the granted performance-based stock awards was met, therefore performance-based award stock compensation of $2.8 million was recorded. As of December 31, 2022, there were 2,218,925 unvested performance-based awards subject to certain performance criteria for vesting. The vesting period for RSU awards is generally three years. Total remaining compensation expense for RSU awards to be recognized under the 2021 Equity Incentive Plan is $22.4 million as of December 31, 2022, and will be amortized on a straight-line basis over the remaining vesting periods. Total remaining compensation expense for performance-based stock awards to be recognized will be recognized over the requisite service periods once the performance-based conditions are deemed to be probable. During the year ended December 31, 2022, 2021 and 2020, stock compensation expense of $4.7 million, $4.5 million and $1.6 million, respectively, was recognized in general and administrative expenses on the Consolidated Statements of Operations and Comprehensive Income (Loss). During the year ended December 31, 2022, 2021 and 2020 stock compensation expense of $2.5 million, $1.3 million and $0.1 million, respectively, was recognized in research and development expenses on the Consolidated Statements of Operations and Comprehensive Income (Loss). Total remaining compensation expense to be recognized under the Stock Plans was $27.0 million as of December 31, 2022, and will be amortized on a straight-line basis over the remaining vesting periods of approximately 1.67 years for stock options, 2.70 years for RSU awards and over the requisite service period once considered probable for performance-based stock awards .

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income before provision for income taxes consisted of the following: (in thousands) December 31, 2022 December 31, 2021 United States $ 81,269 $ 43,645 International (2,700) (1,555) Income before provision for income taxes $ 78,569 $ 42,090 The federal and state income tax expense is summarized as follows: (in thousands) December 31, 2022 December 31, 2021 Current Federal $ — $ — State 3 3 International — — Total current tax expense $ 3 $ 3 Deferred Federal $ — $ — State — — International — — Total deferred tax expense $ — $ — Total tax expense $ 3 $ 3 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and operating losses and tax credit carryforwards. The tax effects of significant items comprising the Company's deferred taxes are as follows: (in thousands) December 31, 2022 December 31, 2021 Deferred tax assets Net operating loss carryforwards $ 27,210 $ 24,899 Available for Sale Securities 2,064 390 Lease liability 532 341 Other 1,580 230 Fixed assets and intangibles 25 89 Capitalized research and development costs 1,929 — Total deferred tax assets $ 33,340 $ 25,949 Deferred tax liabilities ROU asset $ (515) $ (344) Fixed assets and intangibles (479) — Total deferred tax liabilities $ (994) $ (344) Valuation allowance $ (32,346) $ (25,605) Net deferred taxes $ — $ — ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is more likely than not. Realization of the future tax benefits is dependent on the Company's ability to generate sufficient taxable income within the carryforward period. Because of the Company's recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance. The valuation allowance increased by $6.7 million and $6.9 million for the years ended December 31, 2022 and 2021, respectively. At December 31, 2022, we had federal net operating loss carryforwards of approximately $110.2 million to offset future federal taxable income, with $42.0 million available through 2037 and $68.2 million available indefinitely. We don't have any state net operating loss carryforwards, but we had foreign net operating loss carryforwards of approximately $8.5 million that may offset future foreign taxable income through 2042. At December 31, 2022, the Company has research and experimentation credit carryforwards of zero for foreign tax purposes that expire after 2038. The effective tax rate of the Company's provision (benefit) for income taxes differs from the federal statutory rate as follows: December 31, 2022 December 31, 2021 Statutory rate 21.0 % 21.0 % State tax 1.1 (1.3) Warrants, BCF, and other equity items (28.7) (33.3) Valuation allowance 6.4 15.6 Other 0.7 (0.2) Foreign rate differential (0.2) (0.2) Stock-based compensation (0.3) (1.6) Total — % — % The effective tax rate of the Company's provision (benefit) for income taxes differs from the federal statutory rate as follows: December 31, 2022 December 31, 2021 Statutory rate $ 16,500 $ 8,833 State tax 875 (563) Warrants, BCF, and other equity items (22,559) (14,002) Valuation allowance 5,040 6,552 Other 502 (72) Foreign rate differential (148) (85) Stock-based compensation (207) (660) Total $ 3 $ 3 Under certain provisions of the Internal Revenue Code of 1986, as amended, a portion of the federal and state net operating loss carryforwards may be subject to an annual utilization limitation as a result of a change in ownership of the Company. Federal and California tax laws impose significant restrictions on the utilization of net operating loss carryforwards in the event of a change in ownership of the Company, as defined by Internal Revenue Code Section 382 (“Section 382”). The Company has experienced ownership changes as defined by IRC Section 382 and the impact of those changes has been reflected in the consolidated financial statements. In addition, in the future the Company may experience ownership changes, which may limit the utilization of net operating loss carryforwards or other tax attributes. There were no unrecognized tax benefits in the years ended December 31, 2022 and 2021. The Company files income tax returns in the United States, various US states, and Canada. All tax years remain open in all jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other foreign jurisdictions. The Company does not anticipate any significant changes within 12 months of this reporting date of its uncertain tax positions.

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2022
Leases [Abstract]
Leases	Leases The Company leases office space and research and development space in Sacramento, California and Sarnia, Ontario under noncancelable lease agreements and leases various office equipment, warehouse space, and temporary fencing. The operating leases have remaining lease terms of one During 2021, the Company entered into a seven-year lease agreement for office space in Sacramento, California and recorded an operating lease ROU asset of approximately $0.9 million. Also in 2021, the Company entered into an 18-month lease agreement for office space in Sarnia, Ontario and recorded an operating lease right-of-use asset of approximately $0.1 million. The Company also entered into certain other operating leases during 2021 which were not individually or in aggregate material to the Company’s consolidated financial statements. During 2021, the Company amended two of its existing office leases in Sacramento, California. One of these amendments increased the lease payments and extended the lease agreement through October 2028. The other amendment was for an additional space which was effective early 2022 through October 2028. The Company also entered into other operating leases during 2022 which were not individually or in aggregate material to the Company's consolidated financial statements. The Company elected the accounting policy election to account for lease and nonlease components as a single lease component for all asset classes. Further, the Company elects to recognize lease payments on short-term leases in profit or loss on straight-line basis over the lease term for all asset classes, excluding such leases from recognition requirements under Topic 842. Prior to the adoption of Topic 842 on January 1, 2021, the Company recognized operating lease costs on a straight-line basis once control of the space was achieved. Rent expense was $0.3 million for fiscal 2020. The components of lease cost were as follows: (in thousands) December 31, 2022 December 31, 2021 Operating lease cost $ 671 $ 324 Variable lease cost 107 68 Total lease cost $ 778 $ 392 Other information related to leases is as follows: (in thousands) December 31, 2022 December 31, 2021 Operating lease ROU asset (included within Lease right-of-use asset) $ 2,779 $ 1,782 Weighted average remaining lease term (in years): Operating leases 5.28 7.44 Weighted average discount rate: Operating leases 3.4 % 2.8 % (in thousands) December 31, 2022 December 31, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 572 $ 271 ROU assets obtained in exchange for operating lease liabilities $ 1,687 $ 2,062 To calculate the ROU assets and liabilities, the Company uses the discount rate implicit in lease agreements when available. When the implicit discount rates are not readily determinable, the Company uses the incremental borrowing rate, determined as of the date of adoption for Topic 842. This rate was determined for individual leases based on available information regarding jurisdiction, lease term, and asset class. Further, the interest environment was considered, including analysis of benchmark rates from promissory notes, credit curve yields for bonds, and synthetic curves based on discount margin spreads. Maturities of lease liabilities as of December 31, 2022 were as follows: (in thousands) December 31, 2022 2023 $ 703 2024 563 2025 465 2026 479 2027 493 Thereafter 422 Total lease payments 3,125 Less: imputed interest (257) Less: lease liabilities, current (619) Lease liabilities, non-current $ 2,249

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Commitments In connection with the closing of the Business Combination, the Company entered into the Investor Rights Agreement on June 25, 2021 (the “Investor Rights Agreement”), pursuant to which the holders of Registrable Securities (as defined therein) became entitled to, among other things, customary registration rights, including demand, piggy-back and shelf registration rights. The Investor Rights Agreement also provides that the Company will pay certain expenses relating to such registrations and indemnify the registration rights holders against (or make contributions in respect of) certain liabilities which may arise under the Securities Act. On July 15, 2021, the Company registered the Registrable Securities for resale pursuant to a Registration Statement on Form S-1, as amended (File No. 333-257931), which became effective on July 30, 2021. The Company filed Post-Effective Amendment No. 2 to the Registration Statement on Form S-1 on Form S-3 (File No. 333-257931), which became effective on August 8, 2022. In May 2018, the Company executed operating and maintenance agreements for certain services, to facilitate the development and thus bring Origin 1 to the condition necessary for its intended use, commencing in different periods between July 2018 and September 2019, and all generally for five-year periods. The agreements are generally automatically extended for one-year periods thereafter. The agreements include annual fixed payments subject to escalation clauses at the beginning of each calendar year, as defined in the agreement. The minimum fixed payments are $0.4 million per year over the fixed term. Certain of the agreements include quantities that are based on volumes, as defined in the applicable agreements. The Company is also responsible for applicable taxes under these agreements. The total amount capitalized into Property, Plant and Equipment, Net under the agreement was $1.5 million and $0.4 million during the year ended December 31, 2022 and 2021, respectively. In May 2019, the Company also concurrently executed a take-or-pay steam supply agreement commencing by October 1, 2019, through December 31, 2022, whereby the Company will receive up to 25% for the first year and 50% thereafter of the steam generated, up to 140,000 MMBTUs per year. The price paid for the steam is based on a fixed amount plus the supplier’s cost of natural gas, as defined in the agreement. The total amount capitalized into Property, Plant and Equipment, Net under the agreement was $0.6 million and $0.3 million during the year ended December 31, 2022 and 2021, respectively. From time to time the Company enters into a joint development agreement (the "JDA") with unrelated third parties to assist in the development of various products and processes. The agreements range from two In July 2017, the Company entered into a nonexclusive patent license agreement for $0.1 million, which expires upon expiration of the last to expire of the licensed patents. Under this agreement, the Company will pay less than $0.1 million minimum royalty payments per year and, if the Company develops and sells certain products based on the licensed patents. Certain products that Origin is currently developing and anticipates selling are expected to utilize these patents. In December 2016, the Company entered into a patent license agreement for $0.5 million, which expires upon expiration of the last to expire of the licensed patents. Under this agreement, if the Company develops and sells specific products based on the patents, the Company would pay a royalty up to a cumulative $0.5 million from Origin 1, whereby no further payments will be due for any production at Origin 1. If production of those products occurs at subsequent facilities, the Company will pay an upfront license fee royalty and a variable royalty based on production at that subsequent facility, capped at an aggregate $10 million per facility. Certain products that the Company is currently developing and anticipates selling are expected to utilize these patents. No payments were made during the year ended December 31, 2022, 2021 or 2020. In November 2016, the Company entered into a nonexclusive patent license agreement, which expires upon expiration of the patent. Under this agreement, if the Company produces products based on the patent, the Company will pay an annual royalty upon commencement of operations on Origin 1 which will not exceed $1.0 million cumulatively. The pipeline of Company products and sales are not currently expected to be subject to this patent. The annual royalty payments is less than $0.1 million. In September 2011, the Company entered into a nonexclusive patent license agreement, which expires upon expiration of the patent. Under this agreement, if the Company develops and sells specific products based on the patent, the Company would pay a royalty up to $2.0 million per year and $10.0 million in the aggregate. Certain products that the Company is currently developing and anticipates selling are expected to utilize these patents. No payments were made during the year ended December 31, 2022, 2021 or 2020. In June 2011, the Company entered into a nonexclusive patent license agreement, which expires upon expiration of the licensed patent. Under this agreement, the Company pays less than $0.1 million royalty fee annually and if the Company develops and sells specific products based on the patent, 0.4% of net sales. The pipeline of Company products and sales are not currently expected to be subject to this patent. In February 2023, the Company entered into a nonexclusive patent license agreement for use in connection with production at a specific licensed facility. The license expires upon cessation of production at that facility. The Company made a nonrefundable €5 million deposit in 2022 toward securing the license and, as a result of signing the license agreement, will make an additional payment of €7.5 million and may make additional payments depending on the achievement of certain milestones. In connection with this license, the Company entered into a conditional offtake agreement under which the licensor will supply the Company from its plants with a certain amount of the same type of products to be produced at the licensed facility in order to accelerate market development for these products and related applications. Contingencies At times there may be claims and legal proceedings generally incidental to the normal course of business that are pending or threatened against the Company. Although the Company cannot predict the outcome of these matters when they arise, in the opinion of management, any liability arising from them will not have a material adverse effect on the consolidated financial position, results of operations, or liquidity of the Company. At December 31, 2022 and December 31, 2021, there were no claims or legal proceedings pending or threatened against the Company.

Basic and Diluted Net Income (L

Basic and Diluted Net Income (Loss) Per Share	12 Months Ended
Basic and Diluted Net Income (Loss) Per Share	Dec. 31, 2022
Earnings Per Share [Abstract]
Basic and Diluted Net Income (Loss) Per Share	Basic and Diluted Net Income (Loss) Per Share The following table sets forth the computation of basic and diluted net income (loss) per share attributable to common stockholders, which excludes Sponsor Vesting Shares which are legally outstanding, but subject to return to the Company. Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing net income (loss) for the period by the weighted-average number of common shares outstanding during the period, plus the dilutive effect of the stock options, RSU awards, and convertible preferred stock warrants, as applicable pursuant to the treasury stock method, and the convertible notes, as applicable pursuant to the if-converted method. The following table sets forth the computation of basic and diluted net income (loss) per share: (In thousands, except for share and per share amounts) Year Ended December 31, 2022 2021 2020 Numerator: Net income (loss) attributable to common stockholders—Basic $ 78,569 $ 42,090 $ (30,302) Net income (loss) attributable to common stockholders—Diluted $ 78,569 $ 42,090 $ (30,302) Denominator: Weighted-average common shares outstanding—Basic (1) 137,563,877 101,221,781 62,544,933 Stock options 4,571,301 4,954,919 — RSU awards 11,589 61,054 — Weighted-average common shares outstanding—Diluted (1) 142,146,767 106,237,754 62,544,933 Net income (loss) per share—Basic $ 0.57 $ 0.42 $ (0.48) Net income (loss) per share—Diluted $ 0.55 $ 0.40 $ (0.48) (1) Excludes weighted-average Sponsor Vesting Shares subject to return of 4,500,000 and 2,342,466 shares for the year ended December 31, 2022 and 2021, respectively. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. The following potentially dilutive securities for common stock were outstanding and excluded from diluted earnings per share as they are subject to performance or market conditions that were not achieved as follows: Year Ended December 31, 2022 2021 2020 Options to purchase common stock 1,481,531 1,481,531 — Performance-based stock awards 2,218,925 2,137,500 — Earnout shares 25,000,000 25,000,000 — Sponsor vesting shares 4,500,000 4,500,000 — The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net income (loss) per sha re attributable to common stockholders for the periods presented because including them would have been antidilutive: Year Ended December 31, 2022 2021 2020 Options to purchase common stock — — 8,222,710 Warrants to purchase common stock 35,476,667 35,476,667 — Warrants to purchase redeemable convertible preferred stock, as-converted — 2,678,320 5,554,470

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). Pursuant to the Merger Agreement, the merger between Merger Sub and Legacy Origin was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, Artius was treated as the “acquired” company and Legacy Origin was treated as the acquirer for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of Legacy Origin issuing stock for the net assets of Artius, accompanied by a recapitalization. The net assets of Artius are stated at historical cost, with no goodwill or other intangible assets recorded. Legacy Origin was determined to be the accounting acquirer based on the following predominant factors: • the Company’s Board and management are primarily composed of individuals associated with Legacy Origin; • Legacy Origin’s senior management comprise the senior management roles of the Company and are responsible for the day-to-day operations; • the Company assumed the “doing business as” name of the Legacy Origin; and • The intended strategy and operations of the Company continue Legacy Origin’s current strategy and operations as a carbon negative materials company with a mission to enable the world’s transition to sustainable materials.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of commitments and contingencies at the date of the financial statements as well as reported amounts of expenses during the reporting periods. Estimates made by the Company include, but are not limited to, those related to the valuation of common stock and valuation of convertible preferred stock warrants prior to the Business Combination, valuation of the earnout liability, valuation of assumed common stock warrants liability, carrying amount and useful lives of property and equipment and intangible assets, impairment assessments, marketable securities, stock-based compensation expense, probabilities of achievement of performance conditions on performance stock awards, among others. The Company bases these estimates on historical experience and on various other assumptions that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements have been prepared in accordance with U.S. GAAP and applicable rules and regulations of the SEC and include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash, cash equivalents, and marketable securities accounts with a financial institution where, at times, deposits exceed federal insurance limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality. The Company has not experienced any losses on these deposits.
Cash and Cash Equivalents and Restricted Cash	Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with an initial maturity of three months or less at the date of purchase to be cash equivalents. The Company maintains such funds in cash deposits and money market accounts.
Marketable Securities	Marketable Securities The Company’s investment policy requires the Company to purchase investments that meet the definition of available-for-sale securities. The Company does not buy and hold securities principally for the purpose of selling them in the near future. The Company’s policy is focused on the preservation of capital, liquidity, and return. The Company considers all of its marketable debt securities as available for use in current operations, including those with maturity dates beyond one year, and therefore classifies these securities within current assets on the consolidated balance sheets. Securities are classified as available for sale and are carried at fair value, with the change in unrealized gains and losses, net of tax, reported as a separate component on the consolidated statements of comprehensive income until realized. Fair value is determined based on quoted market rates when observable or utilizing data points that are observable, such as quoted prices, interest rates and yield curves. Securities with an amortized cost basis in excess of estimated fair value are assessed to determine what amount of the excess, if any, is caused by expected credit losses. Expected credit losses on securities are recognized in other income (expense), net on the consolidated statements of operations and comprehensive income (loss), and any remaining unrealized losses, net of taxes, are included in accumulated other comprehensive income (loss) in the consolidated statements of redeemable convertible preferred stock, stockholders' equity and accumulated other comprehensive income (loss). For the purposes of computing realized and unrealized gains and losses, the cost of securities sold is based on the specific-identification method. Interest on securities classified as available for sale is included as a component of interest income within other income (expense).
Derivative Financial Instruments	Derivative Financial Instruments The Company evaluated the stockholder convertible notes payable in accordance with ASC 815, Derivatives and Hedging and determined that the embedded components of these contracts qualify as a derivative to be separately accounted for as a liability. The Company records the fair value of the embedded components in accordance with ASC 815, Derivatives and Hedging . The fair value of the derivatives was calculated using a model that estimated the value that would be paid to transfer the liability in an orderly transaction between market participants at the measurement date. The fair value of the derivative liabilities is revalued on each balance sheet date with a corresponding gain or loss recorded in the Consolidated Statements of Operations and Comprehensive Income (Loss). The Company enters into foreign currency derivative contracts with financial institutions to reduce foreign exchange risk related to marketable securities. The Company uses forward currency derivative contracts to minimize the Company’s exposure to balances primarily denominated in the British Pound Sterling and Australian Dollar. The Company’s foreign currency derivative contracts, which are not designated as hedging instruments, are used to reduce the exchange rate risk associated primarily with marketable securities. The Company’s derivative financial instruments program is not designated for trading or speculative purposes. Outstanding foreign currency derivative contracts are recorded at fair value on the consolidated balance sheets.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company applies the fair value measurement accounting standard whenever other accounting pronouncements require or permit fair value measurements. Fair value is defined in the accounting standard as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy under current accounting guidance prioritizes the inputs to valuation techniques used to measure fair value into three broad levels (Level 1, Level 2, and Level 3). Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable inputs for the asset or liability and reflect the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk) in a principal market. The carrying amounts of working capital balances approximate their fair values due to the short maturity of these items. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest rate, currency, or credit risks arising from its financial instruments. We have determined the fair value of debt approximates the carrying value due to the standard terms of the arrangement including but not limited to the amount borrowed, the term, and the interest rate.
Other Receivables	Other Receivables Other receivables consist of amounts due from foreign governmental entities related to the Canadian harmonized sales tax ("HST") and goods and services tax ("GST") for goods and services transacted in Canada, and amounts due from cash collateral held by others for foreign currency derivative contracts.
AgriScience Grant	AgriScience Grant In January 2019, the Company entered into an agreement in which it will participate in the AgriScience Program Cluster Component grant through the Canadian Agricultural Partnership, whereby the Company will receive reimbursements for eligible expenditures up to approximately $1.8 million (in Canadian dollars) through March 2023. Grants are received through reimbursements from the Canadian government and recognized, upon completion of scope of services on a quarterly basis. Grants are recognized as a reduction of property, plant, and equipment or expense based on the nature of the cost the grant is reimbursing.
Property, Plant, and Equipment	Property, Plant, and Equipment Property, plant, and equipment are recorded at cost and depreciated or amortized using the straight-line method over the estimated useful lives of the respective assets. Existing useful lives range from 3 to 5 years. Leasehold improvements are amortized using the straight-line method over the shorter of their estimated useful lives or the lease term. Major additions and improvements are capitalized, while replacements, repairs, and maintenance that do not extend the life of an asset are charged to operations. We depreciate plants over a maximum life of 40 years and plant improvements over the shorter of the asset life or remaining useful life of the plants structure using the straight-line method. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts. Costs incurred to acquire, construct or install property, plant, and equipment during the construction stage of a capital project and costs capitalized in conjunction with major improvements that have not yet been placed in service are recorded as construction in progress, and accordingly are not currently being depreciated. The Company capitalizes interest cost incurred on funds used to construct property, plant and equipment.
Intangible Assets	Intangible Assets Intangible assets are recorded at cost and are amortized using the straight-line method over the estimated useful lives of the respective assets, ranging from 7 to 15 years. The cost of servicing the Company’s patents is expensed as incurred. Upon retirement or sale, the cost of intangible assets is disposed of and the related accumulated amortization is removed from the accounts.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews its long-lived assets, including property, equipment, software and intangibles, for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be fully recoverable. If indicators of impairment exist, management identifies the asset group which includes the potentially impaired long-lived asset, at the lowest level at which there are separate, identifiable cash flows. If the total of the expected undiscounted future net cash flows for the asset group is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying amount of the asset.
Government Loans	Government Loans Government loans are classified as a noncurrent liability and recorded at amortized cost. Forgiveness of the balances due is recorded through earnings and occurs when there is confirmation from the governmental authority that the Company has complied with the conditions for forgiveness attached to the loan.
Debt Issuance Costs	Debt Issuance Costs The costs incurred in connection with the issuance of debt obligations, principally financing and legal costs, are capitalized. These costs are accreted over the term of the debt using the interest method.
Redeemable Convertible Preferred Stock Warrants Liability	Redeemable Convertible Preferred Stock Warrants Liability Free-standing warrants issued by Legacy Origin for the purchase of shares of its convertible preferred stock were classified as liabilities on the accompanying balance sheets at fair value using an Option-Pricing Model. Prior to the Business Combination, the liability recorded was adjusted for changes in the fair value at each reporting date and recorded as interest expense in the accompanying Consolidated Statements of Operations and Comprehensive Income (Loss). As a result of the Business Combination, the Legacy Origin warrants each converted into a warrant to purchase shares of the Company’s Common Stock converted at the Exchange Ratio. The fair value of the warrants upon consummation of the Business Combination (see Note 4), is adjusted based on the price of the underlying Common Stock, was reclassified to additional paid-in capital.
Assumed Common Stock Warrants Liability	Assumed Common Stock Warrants Liability The Company assumed 24,149,960 public warrants (the “Public Warrants”) and 11,326,667 private placement warrants (the “Private Placement Warrants”, and the Public Warrants together with the Private Placement Warrants, the “Assumed Common Stock Warrants”) upon the Business Combination, all of which were issued in connection with Artius’ initial public offering and entitle each holder to purchase one share of Class A common stock at an exercise price of at $11.50 per share. As of December 31, 2022, 24,149,960 Public Warrants and 11,326,667 Private Placement Warrants are outstanding. The Public Warrants are publicly traded and are exercisable for cash unless certain conditions occur, such as the failure to have an effective registration statement related to the shares issuable upon exercise or redemption by the Company under certain conditions, at which time the warrants may be cashless exercised. The Private Placement Warrants are transferable, assignable or salable in certain limited exceptions. The Private Placement Warrants are exercisable for cash or on a cashless basis, at the holder’s option, and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will cease to be Private Placement Warrants, and become Public Warrants and be redeemable by the Company and exercisable by such holders on the same basis as the other Public Warrants. The Company evaluated the Assumed Common Stock Warrants under ASC 815-40, Derivatives and Hedging-Contracts in Entity’s Own Equity (“ASC 815-40”)
Earnout Liability	Earnout Liability The Company has recorded an earnout liability related to future contingent equity shares related to the Business Combination (Note 13). The Company recorded these instruments as liabilities on the Consolidated Balance Sheets at fair value, with subsequent changes in their respective fair values recognized in earnings at each reporting date.
Leases	Leases The Company has leases for office space and equipment, some of which have escalating rentals during the initial lease term and during subsequent optional renewal periods. The Company accounts for its leases under ASC Topic 842, Leases . The Company recognizes a right-of-use asset and lease liability for leases based on the net present value of future minimum lease payments. Lease expense is recognized on a straight-line basis over the non-cancelable lease term and renewal periods that are considered reasonably certain to be exercised.
Research and Development Cost	Research and Development Cost Costs related to research and development are expensed as incurred.
Stock-Based Compensation	Stock-Based Compensation The Company has issued common stock awards under three equity incentive plans. Origin measures stock options and other stock-based awards granted to employees, directors and other service providers based on their fair value on the date of grant and recognizes compensation expenses of those awards over the requisite service period, which is generally the vesting period of the respective award. For awards with performance conditions, compensation is recorded once there is sufficient objective evidence the performance conditions are considered probable of being met. Origin applies the straight-line method of expense recognition to all awards with only service-based vesting conditions. Origin estimates the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model and the grant date closing stock price for RSU awards and performance awards. The Black-Scholes option-pricing model requires the use of highly subjective assumptions including: • Expected term – The expected term of the options is based on the simplified method, which takes into consideration the grant’s contractual life and vesting period and assumes that all options will be exercised between the vesting date and the contractual term of the option which averages an award’s vesting term and its contractual term. • Expected volatility – The Company uses the trading history of various companies in its industry sector in determining an estimated volatility factor. • Expected dividend – The Company has not declared common stock dividends and does not anticipate declaring any common stock dividends in the foreseeable future. • Forfeiture – The Company estimates forfeitures based on historical activity and considers voluntary and involuntary termination behavior as well as analysis of actual historical option forfeitures, netting the estimated expense by the derived forfeiture rate. • Risk-free interest rate
Income Taxes	Income Taxes Deferred income taxes are determined using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is recorded when the expected recognition of a deferred income tax asset is considered to be unlikely.
Functional Currency Translation	Functional Currency Translation The functional currency of the Company’s wholly-owned Canadian subsidiaries is the Canadian dollar, whereby their assets and liabilities are translated at period-end exchange rates except for nonmonetary capital transactions and balances, which are translated at historical rates. All income and expense amounts of the Company are translated at average exchange rates for the respective period. Translation gains and losses are not included in determining net loss but are accumulated in a separate component of stockholders’ equity. Foreign currency transaction gains and losses are included in the determination of net loss in the period in which they occur. These amounts are included in other income, net, of the Consolidated Statements of Operations and Comprehensive Income (Loss).
Comprehensive Income (Loss)	Comprehensive Income (Loss) The Company’s comprehensive income or loss consists of net income or loss and other comprehensive income (loss). Foreign currency translation gains or losses and unrealized gains or losses on available-for-sale marketable debt securities are included in the Company’s other comprehensive income (loss).
Basic and Diluted Net Income (Loss) Per Share	Basic and Diluted Net Income (Loss) Per Share Basic net income (loss) per common share is calculated by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For the purposes of the diluted net income (loss) per share calculation, the convertible preferred stock, common stock options, RSU awards, performance stock awards, convertible preferred stock warrants, common stock warrants, convertible notes, earnout shares, and Sponsor Vesting Shares (as defined below) are considered to be potentially dilutive securities. Basic and diluted net income (loss) per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. All series of the Company’s convertible preferred stock are considered to be participating securities because, in addition to cumulative dividends, all holders are entitled to receive a non-cumulative dividend on a pari passu
Reclassifications	Reclassifications Certain amounts in prior periods have been reclassified to conform with the report classifications of the year ended December 31, 2021, noting the Company has reflected the Reverse Recapitalization pursuant to the Business Combination for all periods presented within the Consolidated Balance Sheets and Consolidated Statements of Redeemable Convertible Preferred Stock, Stockholders’ Equity and Accumulated Other Comprehensive Income (Loss).
Segment Reporting	Segment Reporting The Company operates in a single segment. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company has determined that its Co-Chief Executive Officers are the CODM. To date, the Company’s CODM has made such decisions and assessed performance at the Company level.
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity’s own equity. The guidance is effective for fiscal years beginning on or after December 15, 2021, with early adoption permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted the new standard as of January 1, 2022. The adoption of the standard had no material impact on the Company’s financial results. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform ("Topic 848"): Facilitation of the Effects of Reference Rate Reform on Financial Reporting , as amended and supplemented by subsequent ASUs (collectively, “ASU 2020-04”), which provides practical expedients for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. This guidance is applicable for borrowing instruments, which use LIBOR as a reference rate, and is effective immediately, but is only available through December 31, 2022. The Company adopted the new standard as of January 1, 2022. The adoption of the standard had no material impact on the Company’s financial results. In November 2021, the FASB issued ASU 2021-10, Government Assistance ("Topic 832"), Disclosures by Business Entities about Government Assistance . The FASB issued this update to increase the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements. The main provisions of this update require the following disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy: (i) Information about the nature of the transactions and the related accounting policy used to account for the transactions (ii) The line items on the balance sheet and income statement that are affected by the transactions, and the amounts applicable to each financial statement line item (iii) Significant terms and conditions of the transactions, including commitments and contingencies. The amendments in this update are effective for the Company in the annual period beginning after December 15, 2021. Early application of the amendments is permitted. The Company has elected to adopt on January 1, 2022. The adoption of the standard had no impact on the Company’s financial results. See Note 3 and Note 14 for required disclosures. Recently Issued Accounting Pronouncements Not Yet Adopted In October 2021, the FASB issued ASU 2021-08, Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers . This update improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to (1) recognition of an acquired contract liability; and (2) payment terms and their effect on subsequent revenue recognized by the acquirer. Specifically, the update requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC Topic 606, Revenue from Contracts with Customers . The amendments in this update are effective for the Company in the fiscal year beginning after December 15, 2022, including interim periods within those fiscal years. Early adoption of the amendments is permitted, including adoption in an interim period. The pronouncement is not expected to have a significant impact on the Company's consolidated financial statements. In March 2022, the FASB issued ASU 2022-01, Derivatives and Hedging ("Topic 815") ("ASU 2022-01"). This update clarifies the guidance in Topic 815 on fair value hedge accounting of interest rate risk for portfolios and financial assets. Among other things, the amended guidance established the “last-of-layer” method for making the fair value hedge accounting for these portfolios more accessible and renamed that method the “portfolio layer” method. ASU 2022-01 is effective January 1, 2023 and is not expected to have a significant impact on the Company's consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Cash, Cash Equivalents, and Restricted Cash	Cash, cash equivalents, and restricted cash consisted of the following (in thousands): December 31, 2022 December 31, 2021 Cash and cash equivalents $ 107,858 $ 46,637 Restricted cash 490 490 Total cash, cash equivalents, and restricted cash $ 108,348 $ 47,127
Schedule of Estimated Useful Lives of Assets	The estimated useful lives of assets are as follows: Computer and other equipment 3 years Pilot plant 5 years Machinery and equipment 5 years Leasehold improvements 1-5 years Plants and improvements 20-40 years

Business Combination (Tables)

Business Combination (Tables)	12 Months Ended
Business Combination (Tables)	Dec. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Summary of Element of the Net Proceeds of Business Combination	The following table summarizes the elements of the net proceeds from the Business Combination at the date of acquisition (in thousands): Cash—Trust Account (net of redemptions of $439.0 million) $ 260,448 Cash 60 Cash—PIPE & Backstop Financing 243,000 Non-cash net assets assumed from Artius 40 Less: Fair value of assumed common stock warrants (83,370) Less: Underwriting fees and other issuance costs paid prior to the date of acquisition (34,773) Additional Paid-in-Capital from Business Combination, net of issuance costs paid $ 385,405 Less: Non-cash net assets assumed from Artius (40) Add: Non-cash fair value of assumed common stock warrants 83,370 Add: Other issuance costs included in accounts payable and accrued liabilities 761 Less: Accrued liabilities extinguished through proceeds from Business Combination (1,966) Cash proceeds from the Business Combination $ 467,530
Summary of Number Shares of Common Stock Outstanding	The following table summarizes the number of shares of Common Stock outstanding immediately following the consummation of the Business Combination: Artius shares outstanding prior to the Business Combination, including 4,500,000 Sponsor Vesting Shares 90,562,500 Less: redemption of Artius shares (43,880,956) Shares issued pursuant to the PIPE and Backstop Financing 24,300,001 Business Combination and PIPE Financing shares, including 4,500,000 Sponsor Vesting Shares 70,981,545 Conversion of Legacy Origin Series A preferred stock for common stock 33,783,099 Conversion of Legacy Origin Series B preferred stock for common stock 19,755,784 Conversion of Legacy Origin Series C preferred stock for common stock 6,286,349 Conversion of Legacy Origin convertible notes for common stock 2,049,212 Conversion of Legacy Origin common stock for common stock 2,838,041 Issuance of common stock upon exercise of warrants 5,554,440 Total shares of the Company common stock outstanding immediately following the Business Combination 141,248,470

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
Fair Value Measurement (Tables)	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Summary Of Assets And Liabilities Measured At Fair Value	The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used for such measurements were as follows: Fair Value as of December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Assets: Cash, cash equivalents and restricted cash $ 108,348 $ — $ — $ 108,348 Marketable securities — 215,464 — 215,464 Total fair value $ 108,348 $ 215,464 $ — $ 323,812 Liabilities: Assumed common stock warrants (Public) $ 21,015 $ — $ — $ 21,015 Assumed common stock warrants (Private Placement) — 9,856 — 9,856 Earnout liability — — 42,533 42,533 Derivative liability — 344 — 344 Total fair value $ 21,015 $ 10,200 $ 42,533 $ 73,748 Fair Value as of December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Assets: Cash, cash equivalents and restricted cash $ 47,127 $ — $ — $ 47,127 Marketable securities — 397,458 — 397,458 Derivative asset — 202 — 202 Total fair value $ 47,127 $ 397,660 $ — $ 444,787 Liabilities: Assumed common stock warrants (Public) $ 35,983 $ — $ — $ 35,983 Assumed common stock warrants (Private Placement) — 16,877 — 16,877 Earnout liability — — 127,757 127,757 Derivative liability — 103 — 103 Total fair value $ 35,983 $ 16,980 $ 127,757 $ 180,720
Schedule of Marketable Securities	The Company’s marketable securities that are measured at fair value on a recurring basis and are categorized using the fair value hierarchy. Amortized cost net of unrealized gain (loss) is equal to fair value. The following table summarized the marketable securities by major security type as follows: As of December 31, 2022 (in thousands) Investments Classified as Marketable Securities Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper $ 17,568 $ 38 $ — $ 17,606 Corporate bonds 115,134 — (4,923) 110,211 Asset-backed securities 70,825 8 (3,885) 66,948 U.S. government and agency securities 19,308 — (917) 18,391 Foreign government and agency securities 375 — (37) 338 Municipal/provincial bonds and other 2,000 — (30) 1,970 Total marketable securities $ 225,210 $ 46 $ (9,792) $ 215,464 As of December 31, 2021 (in thousands) Investments Classified as Marketable Securities Amortized Cost Unrealized Gains Unrealized Losses Fair Value Corporate bonds $ 274,939 $ 100 $ (1,725) $ 273,314 Asset-backed securities 96,713 190 (199) 96,704 U.S. government and agency securities 20,235 — (64) 20,171 Foreign government and agency securities 3,262 — (19) 3,243 Municipal/provincial bonds and other 4,000 5 — 4,005 Total $ 399,149 $ 295 $ (2,007) $ 397,437 Pending purchases and sales 21 — — 21 Total marketable securities $ 399,170 $ 295 $ (2,007) $ 397,458
Schedule of Marketable Security Contractual Maturities	The contractual maturities of the investments classified as marketable securities are as follows: As of December 31, 2022 (in thousands) Mature within one year Mature after one year through two years Mature over two years Fair Value Commercial paper $ 17,606 $ — $ — $ 17,606 Corporate bonds 74,797 35,414 — 110,211 Asset-backed securities 1,907 4,833 60,207 66,947 U.S. government and agency securities 7,719 7,480 3,192 18,391 Foreign government and agency securities — 338 — 338 Municipal/provincial bonds and other 1,971 — — 1,971 Total marketable securities $ 104,000 $ 48,065 $ 63,399 $ 215,464 As of December 31, 2021 (in thousands) Mature within one year Mature after one year through two years Mature over two years Fair Value Corporate bonds $ 92,559 $ 134,199 $ 46,556 $ 273,314 Asset-backed securities — 2,000 94,704 96,704 U.S. government and agency securities — 7,995 12,176 20,171 Foreign government and agency securities 2,877 — 366 3,243 Municipal/provincial bonds and other 2,002 2,003 — 4,005 Total $ 97,438 $ 146,197 $ 153,802 $ 397,437 Pending purchases and sales 21 — — 21 Total marketable securities $ 97,459 $ 146,197 $ 153,802 $ 397,458
Summary of Fair Value of Redeemable Convertible Preferred Stock Warrants Liability and Derivative Liability	The following table sets forth a summary of the activities of the Company’s redeemable convertible preferred stock warrant liability and embedded components of the stockholder convertible notes payable, which represents a recurring measurement that is classified within Level 3 of the fair value hierarchy wherein fair value is estimated using significant unobservable inputs: Redeemable Convertible Preferred Stock Warrant Years Ended December 31, (in thousands) 2022 2021 Beginning warrant liability balance $ — $ 19,233 Change in fair value of warrants liability — 35,034 Reclassification to APIC upon recapitalization — (54,267) Ending warrant liability balance $ — $ — Embedded Derivative - Stockholder Convertible Notes Payable Years Ended December 31, (in thousands) 2022 2021 Beginning derivative liabilities balance $ — $ 1,238 Change in fair value — (1,238) Ending derivative liabilities balance $ — $ —

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
Property, Plant and Equipment (Tables)	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property Plant and Equipment	Property, plant, and equipment consisted of the following: (in thousands) December 31, 2022 December 31, 2021 Land $ 11,358 $ 912 Pilot plant 4,599 5,517 Lab equipment 2,526 2,227 Machinery and equipment 948 655 Computer and other equipment 598 388 Construction in process 138,847 55,026 Total 158,876 64,725 Less accumulated depreciation and amortization (4,693) (7,540) Total property, plant, and equipment, net $ 154,183 $ 57,185

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
Intangible Assets (Tables)	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	Intangible assets consisted of the following: (in thousands) December 31, 2022 December 31, 2021 Patents $ 404 $ 432 Less accumulated amortization (244) (217) Total intangible assets $ 160 $ 215

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
Stockholders' Equity (Tables)	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Summary of Stock Option Activity	The following tables summarize stock option activity under the Stock Plans: Outstanding Options Weighted Weighted Average Balance as of December 31, 2020 8,222,710 $ 0.19 8.30 Granted — — Exercised (171,118) 0.42 Forfeited / canceled (158,735) 0.14 Balance as of December 31, 2021 7,892,857 $ 0.19 7.31 Granted — $ — Exercised (1,412,226) 0.28 Forfeited / canceled (9,569) 0.63 Balance as of December 31, 2022 6,471,062 $ 0.17 7.29 Vested and expected to vest at December 31, 2022 6,471,062
Schedule of RSU and Performance Award Activity	The following table summarizes the RSU award and performance-based stock award activity for the December 31, 2022 and 2021: Outstanding Weighted-average grant date fair value Unvested balance at December 31, 2020 — $ — Granted - RSU awards 769,505 7.34 Granted - performance-based stock awards 2,137,500 7.35 Unvested balance at December 31, 2021 2,907,005 $ 7.35 Granted - RSU awards 3,740,946 5.58 Granted - performance-based stock awards 505,500 5.69 RSU awards vested and converted to shares (320,430) 7.34 Vested - performance-based stock awards (391,575) 7.04 Forfeited - RSU awards (36,996) 6.07 Forfeited - performance-based stock awards (32,500) 6.23 Unvested balance at December 31, 2022 6,371,950 $ 6.24 Expected to vest 4,153,025

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Income before Provision for Income Tax	Income before provision for income taxes consisted of the following: (in thousands) December 31, 2022 December 31, 2021 United States $ 81,269 $ 43,645 International (2,700) (1,555) Income before provision for income taxes $ 78,569 $ 42,090
Schedule of Federal and State Income Tax Expense	The federal and state income tax expense is summarized as follows: (in thousands) December 31, 2022 December 31, 2021 Current Federal $ — $ — State 3 3 International — — Total current tax expense $ 3 $ 3 Deferred Federal $ — $ — State — — International — — Total deferred tax expense $ — $ — Total tax expense $ 3 $ 3
Schedule of Deferred Tax Assets and Liabilities	The tax effects of significant items comprising the Company's deferred taxes are as follows: (in thousands) December 31, 2022 December 31, 2021 Deferred tax assets Net operating loss carryforwards $ 27,210 $ 24,899 Available for Sale Securities 2,064 390 Lease liability 532 341 Other 1,580 230 Fixed assets and intangibles 25 89 Capitalized research and development costs 1,929 — Total deferred tax assets $ 33,340 $ 25,949 Deferred tax liabilities ROU asset $ (515) $ (344) Fixed assets and intangibles (479) — Total deferred tax liabilities $ (994) $ (344) Valuation allowance $ (32,346) $ (25,605) Net deferred taxes $ — $ —
Schedule of Effective Tax Rate	The effective tax rate of the Company's provision (benefit) for income taxes differs from the federal statutory rate as follows: December 31, 2022 December 31, 2021 Statutory rate 21.0 % 21.0 % State tax 1.1 (1.3) Warrants, BCF, and other equity items (28.7) (33.3) Valuation allowance 6.4 15.6 Other 0.7 (0.2) Foreign rate differential (0.2) (0.2) Stock-based compensation (0.3) (1.6) Total — % — % The effective tax rate of the Company's provision (benefit) for income taxes differs from the federal statutory rate as follows: December 31, 2022 December 31, 2021 Statutory rate $ 16,500 $ 8,833 State tax 875 (563) Warrants, BCF, and other equity items (22,559) (14,002) Valuation allowance 5,040 6,552 Other 502 (72) Foreign rate differential (148) (85) Stock-based compensation (207) (660) Total $ 3 $ 3

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2022
Leases [Abstract]
Components of Lease Cost and Other Information	The components of lease cost were as follows: (in thousands) December 31, 2022 December 31, 2021 Operating lease cost $ 671 $ 324 Variable lease cost 107 68 Total lease cost $ 778 $ 392 Other information related to leases is as follows: (in thousands) December 31, 2022 December 31, 2021 Operating lease ROU asset (included within Lease right-of-use asset) $ 2,779 $ 1,782 Weighted average remaining lease term (in years): Operating leases 5.28 7.44 Weighted average discount rate: Operating leases 3.4 % 2.8 % (in thousands) December 31, 2022 December 31, 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 572 $ 271 ROU assets obtained in exchange for operating lease liabilities $ 1,687 $ 2,062
Operating Lease Maturity	Maturities of lease liabilities as of December 31, 2022 were as follows: (in thousands) December 31, 2022 2023 $ 703 2024 563 2025 465 2026 479 2027 493 Thereafter 422 Total lease payments 3,125 Less: imputed interest (257) Less: lease liabilities, current (619) Lease liabilities, non-current $ 2,249

Basic and Diluted Net Income _2

Basic and Diluted Net Income (Loss) Per Share (Tables)	12 Months Ended
Basic and Diluted Net Income (Loss) Per Share (Tables)	Dec. 31, 2022
Earnings Per Share [Abstract]
Summary of Basic and Diluted Loss per Ordinary Share	The following table sets forth the computation of basic and diluted net income (loss) per share: (In thousands, except for share and per share amounts) Year Ended December 31, 2022 2021 2020 Numerator: Net income (loss) attributable to common stockholders—Basic $ 78,569 $ 42,090 $ (30,302) Net income (loss) attributable to common stockholders—Diluted $ 78,569 $ 42,090 $ (30,302) Denominator: Weighted-average common shares outstanding—Basic (1) 137,563,877 101,221,781 62,544,933 Stock options 4,571,301 4,954,919 — RSU awards 11,589 61,054 — Weighted-average common shares outstanding—Diluted (1) 142,146,767 106,237,754 62,544,933 Net income (loss) per share—Basic $ 0.57 $ 0.42 $ (0.48) Net income (loss) per share—Diluted $ 0.55 $ 0.40 $ (0.48) (1) Excludes weighted-average Sponsor Vesting Shares subject to return of 4,500,000 and 2,342,466 shares for the year ended December 31, 2022 and 2021, respectively.
Summary of Antidilutive Securities Excluded from Computation of Earnings per Share	The following potentially dilutive securities for common stock were outstanding and excluded from diluted earnings per share as they are subject to performance or market conditions that were not achieved as follows: Year Ended December 31, 2022 2021 2020 Options to purchase common stock 1,481,531 1,481,531 — Performance-based stock awards 2,218,925 2,137,500 — Earnout shares 25,000,000 25,000,000 — Sponsor vesting shares 4,500,000 4,500,000 — The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net income (loss) per sha re attributable to common stockholders for the periods presented because including them would have been antidilutive: Year Ended December 31, 2022 2021 2020 Options to purchase common stock — — 8,222,710 Warrants to purchase common stock 35,476,667 35,476,667 — Warrants to purchase redeemable convertible preferred stock, as-converted — 2,678,320 5,554,470

Risks and Liquidity (Detail)

Risks and Liquidity (Detail) $ in Millions	Dec. 31, 2022 USD ($)
Risks And Liquidity [Abstract]
Cash and cash equivalents, restricted cash and marketable securities	$ 323.8

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Detail) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2019 CAD ($)	Dec. 31, 2022 USD ($) segment plan $ / shares shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($)	Jun. 25, 2021 shares	Sep. 27, 2019 USD ($)
Significant Accounting Policies [Line Items]
Escrow deposit fair value						$ 1,300,000
Escrow deposit		$ 300,000	$ 300,000
Grants received		400,000	0	$ 200,000
Impairment of long lived assets		0	0
Accretion expense for debt issuance cost		$ 0	$ 2,200,000	$ 100,000
Exercise price (in dollars per share) \| $ / shares		$ 11.50
Outstanding warrants (in shares) \| shares		35,476,627	35,476,627
Percent of occurrence of a tender offer or exchange of our stockholders		50%
Number of equity incentive plans (in plans) \| plan		3
Number of operating segments (in segments) \| segment		1
Total assets		$ 493,700,000	$ 510,417,000
Outside United States
Significant Accounting Policies [Line Items]
Total assets		$ 157,200,000	60,600,000
Public Warrants
Significant Accounting Policies [Line Items]
Number of warrants assumed (in shares) \| shares					24,149,960
Outstanding warrants (in shares) \| shares		24,149,960
Private Placement Warrants
Significant Accounting Policies [Line Items]
Number of warrants assumed (in shares) \| shares					11,326,667
Outstanding warrants (in shares) \| shares		11,326,667
Foreign currency contract
Significant Accounting Policies [Line Items]
Derivative, notional amount		$ 21,200,000	63,700,000
Minimum
Significant Accounting Policies [Line Items]
Estimated useful lives		3 years
Intangible assets, estimated useful lives		7 years
Minimum \| Plants and improvements
Significant Accounting Policies [Line Items]
Estimated useful lives		20 years
Maximum
Significant Accounting Policies [Line Items]
Reimbursement for eligible expenditure	$ 1.8
Estimated useful lives		5 years
Intangible assets, estimated useful lives		15 years
Maximum \| Plants and improvements
Significant Accounting Policies [Line Items]
Estimated useful lives		40 years
Standby Letters of Credit
Significant Accounting Policies [Line Items]
Letter of credit		$ 200,000	$ 200,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 107,858	$ 46,637
Restricted cash	490	490
Total cash, cash equivalents, and restricted cash	$ 108,348	$ 47,127	$ 1,874	$ 3,612

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Assets (Detail)	12 Months Ended
	Dec. 31, 2022
Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Computer and other equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Pilot plant
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Machinery and equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Leasehold improvements \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	1 year
Leasehold improvements \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Plants and improvements \| Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	20 years
Plants and improvements \| Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	40 years

Business Combination - Narrativ

Business Combination - Narrative (Detail) $ / shares in Units, $ in Thousands		12 Months Ended
	Jun. 25, 2021 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($)
Business Acquisition [Line Items]
Business combination, net of issuance costs paid	$ 467,530	$ 0	$ 467,530	$ 0
Conversion ratio	2.11
Business combination, acquisition related costs		$ 36,700	$ 36,700
Common stock, shares issued (in shares) \| shares		143,034,225	141,301,569
Common stock, par value (in dollars per share) \| $ / shares		$ 0.0001	$ 0.0001
Artius
Business Acquisition [Line Items]
Business combination, net of issuance costs paid	$ 467,500
PIPE investors
Business Acquisition [Line Items]
Issue of common stocks, Initial public offering (in shares) \| shares	20,000,000
Proceeds from issuance of common stock	$ 200,000
Subscription shares
Business Acquisition [Line Items]
Common stock, shares issued (in shares) \| shares	4,300,001
Common stock, par value (in dollars per share) \| $ / shares	$ 0.0001
Share price (in dollars per share) \| $ / shares	$ 10

Business Combination - Summary

Business Combination - Summary of Element of the Net Proceeds of Business Combination (Detail) - USD ($) $ in Thousands		12 Months Ended
	Jun. 25, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Cash proceeds from the Business Combination	$ 467,530	$ 0	$ 467,530	$ 0
Artius
Business Acquisition [Line Items]
Cash—Trust Account (net of redemptions of $439.0 million)	260,448
Assets Held-in-trust	439,000
Cash	60
Cash—PIPE & Backstop Financing	243,000
Non-cash net assets assumed from Artius	40
Less: Fair value of assumed common stock warrants	(83,370)
Less: Underwriting fees and other issuance costs paid prior to the date of acquisition	(34,773)
Additional Paid-in-Capital from Business Combination, net of issuance costs paid	385,405
Non-cash net assets assumed from Artius	(40)
Add: Non-cash fair value of assumed common stock warrants	83,370
Add: Other issuance costs included in accounts payable and accrued liabilities	761
Less: Accrued liabilities extinguished through proceeds from Business Combination	(1,966)
Cash proceeds from the Business Combination	$ 467,500

Business Combination - Summar_2

Business Combination - Summary of Number Shares of Common Stock Outstanding (Detail) - Artius	Jun. 25, 2021 shares
Business Acquisition [Line Items]
Artius shares outstanding prior to the Business Combination, excluding 4,500,000 Sponsor Vesting Shares (in shares)	90,562,500
Number of vesting shares (in shares)	4,500,000
Less: redemption of Artius shares (in shares)	(43,880,956)
Shares issued pursuant to the PIPE and Backstop Financing (in shares)	24,300,001
Business Combination and PIPE Financing shares, excluding 4,500,000 Sponsor Vesting Shares (in shares)	70,981,545
Conversion of Legacy Origin Series A preferred stock for common stock (in shares)	33,783,099
Conversion of Legacy Origin Series B preferred stock for common stock (in shares)	19,755,784
Conversion of Legacy Origin Series C preferred stock for common stock (in shares)	6,286,349
Conversion of Legacy Origin convertible notes for common stock (in shares)	2,049,212
Conversion of Legacy Origin common stock for common stock (in shares)	2,838,041
Issuance of common stock upon exercise of warrants (in shares)	5,554,440
Total shares of New Origin common stock outstanding immediately following the Business Combination (in shares)	141,248,470

Fair Value Measurement - Summar

Fair Value Measurement - Summary of Assets And Liabilities Measured At Fair Value (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets:
Marketable securities	$ 215,464	$ 397,458
Derivative Asset, Statement of Financial Position [Extensible Enumeration]		Derivative asset
Liabilities:
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Derivative liability
Fair Value, Recurring
Assets:
Cash, cash equivalents and restricted cash	$ 108,348	$ 47,127
Marketable securities	215,464	397,458
Derivative asset		202
Total fair value	323,812	444,787
Liabilities:
Earnout liability	42,533	127,757
Derivative liability	344	103
Total fair value	73,748	180,720
Fair Value, Recurring \| Assumed common stock warrants (Public)
Liabilities:
Warrants or rights outstanding	21,015	35,983
Fair Value, Recurring \| Assumed common stock warrants (Private Placement)
Liabilities:
Warrants or rights outstanding	9,856	16,877
Level 1 \| Fair Value, Recurring
Assets:
Cash, cash equivalents and restricted cash	108,348	47,127
Marketable securities	0	0
Derivative asset		0
Total fair value	108,348	47,127
Liabilities:
Earnout liability	0	0
Derivative liability	0	0
Total fair value	21,015	35,983
Level 1 \| Fair Value, Recurring \| Assumed common stock warrants (Public)
Liabilities:
Warrants or rights outstanding	21,015	35,983
Level 1 \| Fair Value, Recurring \| Assumed common stock warrants (Private Placement)
Liabilities:
Warrants or rights outstanding	0	0
Level 2 \| Fair Value, Recurring
Assets:
Cash, cash equivalents and restricted cash	0	0
Marketable securities	215,464	397,458
Derivative asset		202
Total fair value	215,464	397,660
Liabilities:
Earnout liability	0	0
Derivative liability	344	103
Total fair value	10,200	16,980
Level 2 \| Fair Value, Recurring \| Assumed common stock warrants (Public)
Liabilities:
Warrants or rights outstanding	0	0
Level 2 \| Fair Value, Recurring \| Assumed common stock warrants (Private Placement)
Liabilities:
Warrants or rights outstanding	9,856	16,877
Level 3 \| Fair Value, Recurring
Assets:
Cash, cash equivalents and restricted cash	0	0
Marketable securities	0	0
Derivative asset		0
Total fair value	0	0
Liabilities:
Earnout liability	42,533	127,757
Derivative liability	0	0
Total fair value	42,533	127,757
Level 3 \| Fair Value, Recurring \| Assumed common stock warrants (Public)
Liabilities:
Warrants or rights outstanding	0	0
Level 3 \| Fair Value, Recurring \| Assumed common stock warrants (Private Placement)
Liabilities:
Warrants or rights outstanding	$ 0	$ 0

Fair Value Measurement - Summ_2

Fair Value Measurement - Summary of Marketable Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	$ 225,210	$ 399,170
Unrealized Gains	46	295
Unrealized Losses	(9,792)	(2,007)
Fair Value	215,464	397,458
Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost		399,149
Unrealized Gains		295
Unrealized Losses		(2,007)
Fair Value		397,437
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	115,134	274,939
Unrealized Gains	0	100
Unrealized Losses	(4,923)	(1,725)
Fair Value	110,211	273,314
Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	70,825	96,713
Unrealized Gains	8	190
Unrealized Losses	(3,885)	(199)
Fair Value	66,948	96,704
U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	19,308	20,235
Unrealized Gains	0	0
Unrealized Losses	(917)	(64)
Fair Value	18,391	20,171
Foreign government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	375	3,262
Unrealized Gains	0	0
Unrealized Losses	(37)	(19)
Fair Value	338	3,243
Municipal/provincial bonds and other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	2,000	4,000
Unrealized Gains	0	5
Unrealized Losses	(30)	0
Fair Value	1,970	4,005
Pending purchases and sales
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost		21
Unrealized Gains		0
Unrealized Losses		0
Fair Value		$ 21
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Amortized Cost	17,568
Unrealized Gains	38
Unrealized Losses	0
Fair Value	$ 17,606

Fair Value Measurement - Market

Fair Value Measurement - Marketable Security Contractual Maturities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	$ 104,000	$ 97,459
Mature after one year through two years	48,065	146,197
Mature over two years	63,399	153,802
Fair Value	215,464	397,458
Commercial paper
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	17,606
Mature after one year through two years	0
Mature over two years	0
Fair Value	17,606
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	74,797	92,559
Mature after one year through two years	35,414	134,199
Mature over two years	0	46,556
Fair Value	110,211	273,314
Asset-backed securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	1,907	0
Mature after one year through two years	4,833	2,000
Mature over two years	60,207	94,704
Fair Value	66,947	96,704
U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	7,719	0
Mature after one year through two years	7,480	7,995
Mature over two years	3,192	12,176
Fair Value	18,391	20,171
Foreign government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	0	2,877
Mature after one year through two years	338	0
Mature over two years	0	366
Fair Value	338	3,243
Municipal/provincial bonds and other
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year	1,971	2,002
Mature after one year through two years	0	2,003
Mature over two years	0	0
Fair Value	$ 1,971	4,005
Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year		97,438
Mature after one year through two years		146,197
Mature over two years		153,802
Fair Value		397,437
Pending purchases and sales
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Mature within one year		21
Mature after one year through two years		0
Mature over two years		0
Fair Value		$ 21

Fair Value Measurement - Narrat

Fair Value Measurement - Narrative (Detail) - USD ($)	12 Months Ended
Fair Value Measurement - Narrative (Detail) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant or Right [Line Items]
Sales of marketable securities	$ 3,815,859,000	$ 2,024,089,000	$ 0
Realized (loss) gain on marketable securities	(1,000,000)	200,000	$ 0
Aggregate fair value of marketable securities in unrealized loss position	193,500,000	346,300,000
Allowance for credit loss	0	0
Foreign currency contract
Class of Warrant or Right [Line Items]
Net (loss) gain on foreign currency derivative contracts	$ (400,000)	$ 100,000

Fair Value Measurement - Summ_3

Fair Value Measurement - Summary of Fair Value of Redeemable Convertible Preferred Stock Warrants Liability and Derivative Liability (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Redeemable Convertible Preferred Stock Warrant
Schedule Of Fair Value Of Redeemable Convertible Preferred Stock Warrants Liability And Derivative Liability [Roll Forward]
Beginning balance	$ 0	$ 19,233
Change in fair value	0	35,034
Reclassification to APIC upon recapitalization	0	(54,267)
Ending balance	0	0
Embedded Derivative - Stockholder Convertible Notes Payable
Schedule Of Fair Value Of Redeemable Convertible Preferred Stock Warrants Liability And Derivative Liability [Roll Forward]
Beginning balance	0	1,238
Change in fair value	0	(1,238)
Ending balance	$ 0	$ 0

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property Plant and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 158,876	$ 64,725
Less accumulated depreciation and amortization	(4,693)	(7,540)
Total property, plant, and equipment, net	154,183	57,185
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	11,358	912
Pilot plant
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	4,599	5,517
Lab equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,526	2,227
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	948	655
Computer and other equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	598	388
Construction in process
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 138,847	$ 55,026

Property, Plant and Equipment_2

Property, Plant and Equipment - Narrative (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 0.7	$ 0.5	$ 0.5
Capitalized interest cost	1.1	0.9
Capitalized stock-based compensation	1.9	0.9
Cumulative translation adjustment	$ 3	$ (0.1)

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 404	$ 432
Less accumulated amortization	(244)	(217)
Total intangible assets	$ 160	$ 215

Intangible Assets - Narrative (

Intangible Assets - Narrative (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 0	$ 0	$ 0
Patents
Finite-Lived Intangible Assets [Line Items]
Intangible assets weighted average useful life	4 years 4 months 28 days

Consortium Agreement - Narrativ

Consortium Agreement - Narrative (Detail) - USD ($)	12 Months Ended
Consortium Agreement - Narrative (Detail) - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Transfers and Servicing [Abstract]
Other income	$ 0	$ 500,000	$ 600,000

PPP Loans - Narrative (Detail)

PPP Loans - Narrative (Detail) - PPP Loan $ in Millions	1 Months Ended
PPP Loans - Narrative (Detail) - PPP Loan $ in Millions	Apr. 30, 2020 USD ($)
Debt Disclosure [Line Items]
Unsecured loan	$ 0.9
Loan facility term	2 years
Debt instrument, interest rate	1%

Related Party Transactions - Na

Related Party Transactions - Narrative (Detail) $ in Millions	1 Months Ended							12 Months Ended
	Feb. 28, 2021 USD ($)	Jan. 31, 2021 USD ($)	Nov. 30, 2019 USD ($)	May 31, 2019 USD ($) installment	Aug. 31, 2018 USD ($)	Dec. 31, 2016 USD ($)	Nov. 30, 2016 USD ($)	Dec. 31, 2022 USD ($) agreement repayment customer1	Dec. 31, 2021 USD ($)	Aug. 01, 2022 USD ($)
Debt Disclosure [Line Items]
Company received amount from agreement						$ 0.5
Invested amount for research and development					$ 1.5
Number of offtake supply agreements (in agreements) \| agreement								8
Number of offtake supply agreements with same customer (in agreements) \| agreement								2
Number of customers that can terminate offtake agreement (in customers) \| customer1								2
Initial term of offtake supply agreement								10 years
Number of fixed repayments (in repayments) \| repayment								3
Amendment to repayment period								3 months
Liquidated damages								$ 0.2
Accrued interest								$ 5.4	$ 5.2
Other long-term debt							$ 5
Stockholder
Debt Disclosure [Line Items]
Number of offtake supply agreements (in agreements) \| agreement								5
Line of credit facility, interest rate								5.02%
Debt instrument, increase, accrued interest								$ 0.3	0.1
Other long-term debt								$ 5.1	5.1
Repayment period under prepayment agreement							5 years
Amount of repayment under prepayment agreement							$ 7.5
Repayment percentage of prepayment agreement amount							150%
Loan facility term								5 years
Stockholder \| LIBOR
Debt Disclosure [Line Items]
Line of credit facility, interest rate								0.25%
Unsecured Convertible Notes
Debt Disclosure [Line Items]
Debt conversion, converted instrument, amount	$ 50
Convertible notes	$ 10
Debt instrument, interest rate	8%
Promissory Note
Debt Disclosure [Line Items]
Prepayment from stockholder							$ 5
Debt instrument, increase, accrued interest				$ 0.2
Number of installments (in installments) \| installment				3
Long-term debt, maturity, year two										$ 2.7
Long-term debt, maturity, year three										1.9
Long-term debt, maturity, year four										1.8
Total debt outstanding								$ 5.2	$ 5.2
Promissory Note \| Legacy Stockholder Note
Debt Disclosure [Line Items]
Principal amount										$ 5.2
Bridge Notes
Debt Disclosure [Line Items]
Line of credit facility, maximum borrowing capacity			$ 6
Line of credit facility, interest rate			10%
Conversion percentage of outstanding principal and unpaid accrued interest		70%	70%
Percentage of repay purchasers in cash amount during liquidation			200%
Debt conversion, converted instrument, amount		$ 50
SPAC transaction		$ 700
Bridge Notes \| Unsecured Convertible Notes
Debt Disclosure [Line Items]
Conversion percentage of outstanding principal and unpaid accrued interest	80%
Repayment premium as a percentage of principal	1

Other Liabilities, Long-term -

Other Liabilities, Long-term - Narrative (Detail) - USD ($) $ in Millions	1 Months Ended
	Sep. 30, 2019	Dec. 31, 2022	Dec. 31, 2021	Nov. 30, 2016
Other Liabilities [Line Items]
Other long-term debt				$ 5
Prepayment agreement
Other Liabilities [Line Items]
Other long-term debt	$ 5	$ 2.5	$ 2.5
Percentage of prepayment applied against future purchases	100%
Period of customer capacity reservation	10 years
Prepayment agreement \| Installment 1
Other Liabilities [Line Items]
Debt instrument, periodic payment	$ 2.5
Prepayment agreement \| Installment 2
Other Liabilities [Line Items]
Debt instrument, periodic payment	$ 2.5
Period of payment of prepayment agreement	30 days

Earnout Liability - Narrative (

Earnout Liability - Narrative (Detail) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares
Business Acquisition, Contingent Consideration [Line Items]
Earnout shares of common stock outstanding (in shares) \| shares	25,000,000	25,000,000	0
Post triggering event period	10 days
Sponsor vesting shares (in shares) \| shares	4,500,000	4,500,000	0
Change in fair value of earnout liability \| $	$ 85,437	$ 75,488	$ 0
Earnout liability
Business Acquisition, Contingent Consideration [Line Items]
Earn-out liability \| $	42,500	127,800
Change in fair value of earnout liability \| $	$ 85,400	$ 75,500
Earnout liability \| Dividend yield
Business Acquisition, Contingent Consideration [Line Items]
Measurement input	0
Earnout liability \| Volatility
Business Acquisition, Contingent Consideration [Line Items]
Measurement input	0.70
Earnout liability \| Interest rate
Business Acquisition, Contingent Consideration [Line Items]
Measurement input	0.0408
Earnout liability \| Share trigger price 1
Business Acquisition, Contingent Consideration [Line Items]
Share price (in dollars per share) \| $ / shares	$ 15
Post triggering event period	10 days
Period from businees combination closing date stock price trigger	3 years
Earnout liability \| Share trigger price 2
Business Acquisition, Contingent Consideration [Line Items]
Share price (in dollars per share) \| $ / shares	$ 20
Post triggering event period	10 days
Period from businees combination closing date stock price trigger	4 years
Earnout liability \| Share trigger price 3
Business Acquisition, Contingent Consideration [Line Items]
Share price (in dollars per share) \| $ / shares	$ 25
Post triggering event period	10 days
Period from businees combination closing date stock price trigger	5 years

Canadian Government Research _2

Canadian Government Research and Development Program Liability - Narrative (Detail) $ in Millions, $ in Millions	1 Months Ended
	Apr. 30, 2019 CAD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Apr. 30, 2021
Research and Development [Abstract]
Lesser eligible costs percentage	18.48%
Lesser eligible costs	$ 23
Funding repayment period	15 years
Maximum repayment ratio	1.25
Funding reduction percentage				50%
Minimum costs of commercial plants	$ 500
Commercial plants constructed and operational period	30 months
Funding liability		$ 7.2	$ 6.8

Assumed Common Stock Warrants -

Assumed Common Stock Warrants - Narrative (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Class of Warrant or Right [Line Items]
Number of warrants or rights outstanding (in shares)	35,476,627	35,476,627
Assumed common stock warrants liability	$ 30,872	$ 52,860
Change in fair value of gain, assumed warrants	$ 22,000	$ 30,500
Share trigger price 1
Class of Warrant or Right [Line Items]
Class of warrants redemption price per unit (in dollars per share)	$ 0.01
Class of warrants redemption notice period	30 days
Warrant instrument redemption threshold consecutive trading days	20 days
Trading period	30 days
Public Warrants
Class of Warrant or Right [Line Items]
Warrants issued during the period (in shares)	24,149,960
Number of common stock shares converted (in shares)	1
Share price (in dollars per share)	$ 11.50
Private Placement Warrants
Class of Warrant or Right [Line Items]
Warrants issued during the period (in shares)	11,326,667
Number of common stock shares converted (in shares)	1
Share price (in dollars per share)	$ 11.50
Private Warrant
Class of Warrant or Right [Line Items]
Share price (in dollars per share)	$ 12
Warrant instrument redemption threshold consecutive trading days	20 days
Trading period	30 days
Minimum lock In period required for warrant exercise from the date of business combination	365 days
Number of days for a particular event to get over for determining trading period	150 days
Common Class A \| Minimum
Class of Warrant or Right [Line Items]
Share redemption trigger price per share (in dollars per share)	$ 10
Common Class A \| Maximum
Class of Warrant or Right [Line Items]
Share redemption trigger price per share (in dollars per share)	18
Common Class A \| Share trigger price 1
Class of Warrant or Right [Line Items]
Share redemption trigger price per share (in dollars per share)	$ 18

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Detail) - USD ($)			3 Months Ended	12 Months Ended
Stockholders' Equity - Narrative (Detail) - USD ($)	Jan. 01, 2022	Feb. 16, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Common stock, shares authorized (in shares)				1,000,000,000	1,000,000,000
Common stock, par value (in dollars per share)				$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)				10,000,000	10,000,000
Common stock, voting rights				one
Common stock, shares outstanding (in shares)				143,034,225	141,301,569
Sponsor vesting shares outstanding (in shares)				4,500,000	4,500,000
Stock option plan, exercisable period				10 years
Common stock, shares reserved (in shares)				27,846,011
Stock options available for grant (in shares)				15,728,837	11,285,104
Stock options, exercisable (in shares)				3,588,523	4,130,184
Total intrinsic value of options exercised				$ 8,500,000	$ 300,000
Stock option, aggregate intrinsic value				28,700,000	49,300,000
Nonvested award, cost not yet recognized				4,700,000	6,600,000
Stock-based compensation				7,235,000	5,767,000	$ 1,630,000
Stock compensation not yet recognized				$ 27,000,000
Non employee
Class of Stock [Line Items]
Stock option plan, exercisable period				4 years
General and administrative expense
Class of Stock [Line Items]
Stock-based compensation				$ 4,700,000	4,500,000	1,600,000
Research and development expense
Class of Stock [Line Items]
Stock-based compensation				$ 2,500,000	1,300,000	$ 100,000
Performance and market based awards
Class of Stock [Line Items]
Stock options issued during the period (in shares)						2,920,732
Stock options, vested (in shares)		529,119
Stock-based compensation					$ 2,900,000
Performance and market based awards \| First vesting
Class of Stock [Line Items]
Stock option plan, vesting percentage			2.0833%
Stock options, outstanding (in shares)			529,119
Performance and market based awards \| Second vesting
Class of Stock [Line Items]
Stock options, outstanding (in shares)			2,391,613
Restricted stock units (RSUs)
Class of Stock [Line Items]
Vesting period				2 years 8 months 12 days
Service period				3 years
Restricted stock units (RSUs) \| Tranche one
Class of Stock [Line Items]
Stock option plan, vesting percentage				33.30%
Restricted stock units (RSUs) \| Tranche two
Class of Stock [Line Items]
Stock option plan, vesting percentage				33.30%
Restricted stock units (RSUs) \| Tranche three
Class of Stock [Line Items]
Stock option plan, vesting percentage				33.30%
Stock Options
Class of Stock [Line Items]
Vesting period				1 year 8 months 1 day
Stock compensation not yet recognized, vesting period				1 year 8 months 12 days	2 years 7 months 6 days
Stock options issued during the period (in shares)				0	0
Performance shares
Class of Stock [Line Items]
Fair value of shares vested				$ 3,600,000	$ 0
Stock-based compensation				$ 2,800,000
Unvested outstanding (in shares)				2,218,925
One year from the vesting commencement date
Class of Stock [Line Items]
Stock option plan, vesting percentage				25%
Vesting period				1 year
Employee Stock Purchase Plan (ESPP) \| Employee stock
Class of Stock [Line Items]
Purchase price of common stock, percent				85%
Number of shares authorized (in shares)				3,722,490	1,846,710
Evergreen shares reserve feature period				10 years
Percentage of fully diluted shares of common stock				1%
Increase in number of shares of authorized common stock (in shares)				3,693,420
Number of additional shares authorized (in shares)				1,875,780
Stock Incentive Plan \| More than one year from vesting commencement date
Class of Stock [Line Items]
Stock option plan, vesting percentage				2.778%
The Stock Plans \| Performance shares \| Minimum
Class of Stock [Line Items]
Stock option plan, vesting percentage				0%
The Stock Plans \| Performance shares \| Maximum
Class of Stock [Line Items]
Stock option plan, vesting percentage				300%
Twenty Twenty One Equity Incentive Plan \| Employee stock
Class of Stock [Line Items]
Number of shares authorized (in shares)					18,467,109
Evergreen shares reserve feature period				10 years
Percentage of fully diluted shares of common stock				5%
Number of additional shares authorized (in shares)	9,378,902
Maximum percentage of share reserve, outstanding diluted stock				15%
Twenty Twenty One Equity Incentive Plan \| Restricted stock units (RSUs)
Class of Stock [Line Items]
Stock compensation not yet recognized, vesting period				3 years
Cost not yet recognized, excluding options				$ 22,400,000
Common Stock
Class of Stock [Line Items]
Common stock, shares authorized (in shares)				1,010,000,000	1,010,000,000
Common stock, par value (in dollars per share)				$ 0.0001	$ 0.0001
Warrants issued (in shares)				1,000,000,000	1,000,000,000
Common stock, shares outstanding (in shares)				143,034,225	141,301,569

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Option Activity (Detail) - Options to purchase common stock - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Outstanding Options
Beginning balance (in shares)	7,892,857	8,222,710
Granted (in shares)	0	0
Exercised (in shares)	(1,412,226)	(171,118)
Forfeited / canceled (in shares)	(9,569)	(158,735)
Ending balance (in shares)	6,471,062	7,892,857	8,222,710
Vested and expected to vest (in shares)	6,471,062
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 0.19	$ 0.19
Granted (in dollars per share)	0	0
Exercised (in dollars per share)	0.28	0.42
Forfeited / canceled (in dollars per share)	0.63	0.14
Ending balance (in dollars per share)	$ 0.17	$ 0.19	$ 0.19
Weighted Average Remaining Contractual Life (in years)
Weighted Average Remaining Contractual Life (in years)	7 years 3 months 14 days	7 years 3 months 21 days	8 years 3 months 18 days

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of RSU and Performance Award Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
RSUs and performance shares
Outstanding
Beginning balance (in shares)	2,907,005	0
Ending balance (in shares)	6,371,950	2,907,005
Expected to vest (in shares)	4,153,025
Weighted-average grant date fair value
Beginning balance (in dollars per share)	$ 7.35	$ 0
Ending balance (in dollars per share)	$ 6.24	$ 7.35
RSU awards
Outstanding
Granted (in shares)	3,740,946	769,505
Vested and converted (in shares)	(320,430)
Forfeited (in shares)	(36,996)
Weighted-average grant date fair value
Granted (in dollars per share)	$ 5.58	$ 7.34
Vested and converted (in dollars per share)	7.34
Foreited (in dollars per share)	$ 6.07
Performance-based stock awards
Outstanding
Granted (in shares)	505,500	2,137,500
Vested (in shares)	(391,575)
Forfeited (in shares)	(32,500)
Ending balance (in shares)	2,218,925
Weighted-average grant date fair value
Granted (in dollars per share)	$ 5.69	$ 7.35
Vested (in dollars per share)	7.04
Foreited (in dollars per share)	$ 6.23

Income Taxes - Income before In

Income Taxes - Income before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
United States	$ 81,269	$ 43,645
International	(2,700)	(1,555)
Income before income taxes	$ 78,569	$ 42,090

Income Taxes - Federal and Stat

Income Taxes - Federal and State Income Tax Provision (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Current
Federal	$ 0	$ 0
State	3	3
International	0	0
Total current tax expense	3	3
Deferred
Federal	0	0
State	0	0
International	0	0
Total deferred tax expense	0	0
Total tax expense	$ 3	$ 3

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets
Net operating loss carryforwards	$ 27,210	$ 24,899
Available for Sale Securities	2,064	390
Lease liability	532	341
Other	1,580	230
Fixed assets and intangibles	25	89
Capitalized research and development costs	1,929	0
Total deferred tax assets	33,340	25,949
Deferred tax liabilities
ROU asset	(515)	(344)
Fixed assets and intangibles	(479)	0
Total deferred tax liabilities	(994)	(344)
Valuation allowance	(32,346)	(25,605)
Net deferred taxes	$ 0	$ 0

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Detail) - USD ($)	12 Months Ended
Income Taxes - Narrative (Detail) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Increase in valuation allowance	$ 6,700,000	$ 6,900,000
Federal operating loss carryforward	110,200,000
Operating loss carryforward, foreign	8,500,000
Unrecognized tax benefits	0	$ 0
Domestic
Operating Loss Carryforwards [Line Items]
Operating loss carryforward subject to expiration	42,000,000
Operating loss carryforward not subject to expiration	68,200,000
Foreign
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, research	$ 0

Income Taxes - Effective Tax Ra

Income Taxes - Effective Tax Rate (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Increase (Decrease) in Tax Rate:
Statutory rate	21%	21%
State tax	1.10%	(1.30%)
Warrants, BCF, and other equity items	(28.70%)	(33.30%)
Valuation allowance	6.40%	15.60%
Other	0.70%	(0.20%)
Foreign rate differential	(0.20%)	(0.20%)
Stock-based compensation	(0.30%)	(1.60%)
Effective income tax rate	0%	0%
Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]
Statutory rate	$ 16,500	$ 8,833
State tax	875	(563)
Warrants, BCF, and other equity items	(22,559)	(14,002)
Valuation allowance	5,040	6,552
Other	502	(72)
Foreign rate differential	(148)	(85)
Stock-based compensation	(207)	(660)
Total tax expense	$ 3	$ 3

Leases - Narrative (Detail)

Leases - Narrative (Detail) $ in Thousands	12 Months Ended
Leases - Narrative (Detail) $ in Thousands	Dec. 31, 2021 USD ($) lease	Dec. 31, 2020 USD ($)	Dec. 31, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Operating lease right-of-use asset	$ 1,782		$ 2,779
Number of amended leases (in leases) \| lease	2
Rent expense		$ 300
Sacramento, California lease agreement
Lessee, Lease, Description [Line Items]
Operating lease term	7 years
Operating lease right-of-use asset	$ 900
Sarnia, Ontario lease agreement
Lessee, Lease, Description [Line Items]
Operating lease term	18 months
Operating lease right-of-use asset	$ 100
Minimum
Lessee, Lease, Description [Line Items]
Remaining operating lease term			1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining operating lease term			8 years

Leases - Components of Lease Co

Leases - Components of Lease Cost (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease cost	$ 671	$ 324
Variable lease cost	107	68
Total lease cost	$ 778	$ 392

Leases - Other Information (Det

Leases - Other Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Right of Use Assets:
Operating lease ROU asset (included within Lease right-of-use asset)	$ 2,779	$ 1,782
Weighted average remaining lease term (in years):
Operating leases	5 years 3 months 10 days	7 years 5 months 8 days
Weighted average discount rate:
Operating leases	3.40%	2.80%
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 572	$ 271
Right-of-Use Asset Obtained In Exchange for Lease Liability:
ROU assets obtained in exchange for operating lease liabilities	$ 1,687	$ 2,062	$ 0

Leases - Operating Lease Maturi

Leases - Operating Lease Maturity (Detail) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Leases [Abstract]
2023	$ 703
2024	563
2025	465
2026	479
2027	493
Thereafter	422
Total lease payments	3,125
Less: imputed interest	(257)
Less: lease liabilities, current	(619)	$ (280)
Lease liabilities, non-current	$ 2,249	$ 1,486

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Detail) MMBTU in Thousands, € in Millions

1 Months Ended

12 Months Ended

May 31, 2019

Jul. 31, 2017 USD ($)

Dec. 31, 2016 USD ($)

Nov. 30, 2016 USD ($)

Feb. 28, 2023 EUR (€)

May 31, 2019 MMBTU

May 31, 2018 USD ($)

Sep. 30, 2011 USD ($)

Jun. 30, 2011 USD ($)

Dec. 31, 2022 USD ($)

Dec. 31, 2022 EUR (€)

Dec. 31, 2021 USD ($)

Dec. 31, 2020 USD ($)

Other Commitments [Line Items]

Property, plant, and equipment, net

$ 154,183,000

$ 57,185,000

License payment, royalty payment

$ 0

Patent License Agreement

Other Commitments [Line Items]

Upfront license payment | €

€ 5

Subsequent event | Patent License Agreement

Other Commitments [Line Items]

License payment, royalty payment | €

€ 7.5

Operating and Maintenance Agreement

Other Commitments [Line Items]

Service agreement, periods

5 years

Operating and maintenance agreements, automatic extension periods

1 year

Property, plant, and equipment, net

1,500,000

400,000

Operating and Maintenance Agreement | Minimum

Other Commitments [Line Items]

Operating and maintenance agreements, fixed payments per year

$ 400,000

Take Or Pay Steam Supply Agreement

Other Commitments [Line Items]

Property, plant, and equipment, net

600,000

300,000

Service agreement, percentage of steam receivable thereafter

50%

Take Or Pay Steam Supply Agreement | Maximum

Other Commitments [Line Items]

Service agreement, percentage of steam receivable during first year

25%

Service agreement, MMBtus per year generated | MMBTU | MMBTU

140

Joint Development Agreements

Other Commitments [Line Items]

Property, plant, and equipment, net

$ 0

Joint Development Agreements | Minimum

Other Commitments [Line Items]

Service agreement, periods

2 years

Joint Development Agreements | Maximum

Other Commitments [Line Items]

Service agreement, periods

3 years

Patent License Agreement

Other Commitments [Line Items]

License agreement amount

$ 100,000

$ 500,000

Royalty payment per year

$ 100,000

Royalty payment, cumulative amount

500,000

Annual maximum royalty payment

$ 2,000,000

Maximum royalty payment

$ 10,000,000

Upfront license fee royalty and a variable royalty, aggregate cap per facility

$ 10,000,000

License payment, royalty payment

$ 0

Patent License Agreement | Minimum

Other Commitments [Line Items]

Royalty payment per year

$ 100,000

Patent License Agreement | Maximum

Other Commitments [Line Items]

Royalty payment per year

$ 100,000

Royalty payment, cumulative amount

$ 1,000,000

Nonexclusive Patents Llicense Agreement

Other Commitments [Line Items]

Percentage of net sales

0.40%

Basic and Diluted Net Income _3

Basic and Diluted Net Income (Loss) Per Share - Summary of Basic And Diluted Net Income (Loss) Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Net income (loss) attributable to common stockholders—Basic	$ 78,569	$ 42,090	$ (30,302)
Net income (loss) attributable to common stockholders—Diluted	$ 78,569	$ 42,090	$ (30,302)
Denominator:
Weighted-average common shares outstanding—Basic (in shares)	137,563,877	101,221,781	62,544,933
Weighted-average common shares outstanding—Diluted (in shares)	142,146,767	106,237,754	62,544,933
Net income (loss) per share—Basic (in dollars per share)	$ 0.57	$ 0.42	$ (0.48)
Net income (loss) per share—Diluted (in dollars per share)	$ 0.55	$ 0.40	$ (0.48)
Weighted-average sponsor vesting shares subject to return (in shares)	4,500,000	2,342,466
Options to purchase common stock
Denominator:
Dilutive share based payment arrangements (in shares)	4,571,301	4,954,919	0
RSU awards
Denominator:
Dilutive share based payment arrangements (in shares)	11,589	61,054	0

Basic and Diluted Net Income _4

Basic and Diluted Net Income (Loss) Per Share - Diluted Earnings Per Share Subject to Performance (Detail) - shares	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Options to purchase common stock (in shares)	1,481,531	1,481,531	0
Performance-based stock awards (in shares)	2,218,925	2,137,500	0
Earnout shares (in shares)	25,000,000	25,000,000	0
Sponsor vesting shares (in shares)	4,500,000	4,500,000	0

Basic and Diluted Net Income _5

Basic and Diluted Net Income (Loss) Per Share - Summary of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	0	8,222,710
Warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	35,476,667	35,476,667	0
Warrants to purchase redeemable convertible preferred stock, as-converted
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	2,678,320	5,554,470